var title_f2_13_2256="Soot plugs after airway burn";
var content_f2_13_2256=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe airway burns complicated by hypoxemic respiratory failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest X-ray demonstrates lung hyperinflation (left). Endoscopic view showing proximally impacted soot plugs (top right). Large soot plugs molding the right upper lobe were removed simply by suctioning with a flexible bronchoscope (bottom right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_13_2256=[""].join("\n");
var outline_f2_13_2256=null;
var title_f2_13_2257="Prenatal ultrasound flattened adrenal and renal agenesis";
var content_f2_13_2257=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound flattened adrenal with right renal agenesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flattened right adrenal gland seen on longitudinal view with right renal agenesis (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_13_2257=[""].join("\n");
var outline_f2_13_2257=null;
var title_f2_13_2258="Patient information: Glaucoma (The Basics)";
var content_f2_13_2258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15845\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/32/23042\">",
"         How glaucoma affects vision",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/11/24754\">",
"         Patient information: Age-related macular degeneration (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/35/11826\">",
"         Patient information: Age-related vision loss (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/62/6114\">",
"         Patient information: Cataracts (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/34/11810\">",
"         Patient information: Diabetic retinopathy (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Glaucoma (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/glaucoma-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H7832343\">",
"      <span class=\"h1\">",
"       What is glaucoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Glaucoma is a disease that damages the main nerve in the eye, called the optic nerve. It causes vision loss and can even lead to blindness. There are different types of glaucoma. The most common type in the United States is open-angle glaucoma. This article is about open-angle glaucoma.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7832350\">",
"      <span class=\"h1\">",
"       What are the symptoms of glaucoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;At first, glaucoma does not usually cause symptoms. When it does cause vision loss, it starts by affecting the edges of what you see (",
"      <a class=\"graphic graphic_picture graphicRef77916 \" href=\"UTD.htm?22/32/23042\">",
"       picture 1",
"      </a>",
"      ). In other words, the center of what you look at often looks clear. But things that are off to the side do not. Some people call this &ldquo;tunnel vision.&rdquo; As the disease gets worse, all vision can be affected.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7832357\">",
"      <span class=\"h1\">",
"       Is there a test for glaucoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To check for glaucoma, doctors can use a few different tests. They can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Look into the back of your eye with a magnifying tool and see if there are signs of nerve damage",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Check how well you see things in the center of your vision, and how well you see things that are off to the side",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Check the pressure inside your eye by pushing or blowing on your eye with a special tool. (People with glaucoma often have too much pressure inside the eye.)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Everyone age 40 and older should be tested for glaucoma at least once. Testing helps doctors find and treat the disease early, before it causes symptoms. That&rsquo;s important, because treatment for glaucoma can prevent or slow down vision loss. But it cannot undo damage that has already been done.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7832364\">",
"      <span class=\"h1\">",
"       How is glaucoma treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Effective treatments for glaucoma all work by lowering the pressure inside the eye. There are 3 ways to lower eye pressure: eye drops, surgery, or laser therapy.",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Eye drop medicines",
"        <strong>",
"        </strong>",
"        &ndash; There are 2 main types of glaucoma eye drops:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Prostaglandins",
"       </li>",
"       <li>",
"        Beta blockers",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Laser therapy &ndash; Laser therapy improves the way fluid drains from the eye.",
"        <strong>",
"        </strong>",
"       </li>",
"       <li>",
"        Surgery &ndash; Surgery involves making a small opening or inserting a tiny tube in the eye so that fluid can drain better.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7832371\">",
"      <span class=\"h1\">",
"       Which treatment should I have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Experts recommend that all people start by using eye drops. Some people need to use 2 different eye drop medicines.",
"     </p>",
"     <p>",
"      If your doctor prescribes eye drops, it's very important that you use them every day, as directed. Glaucoma eye drops can keep you from losing your vision. But they only work if you follow the instructions on how to use them. There are now medicines that you can use just once a day.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7832378\">",
"      <span class=\"h1\">",
"       What if drops don&rsquo;t work for me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you try a few different eye drop medicines, and they do not lower your eye pressure enough, your doctor might suggest surgery or laser therapy.",
"     </p>",
"     <p>",
"      Many doctors prefer surgery, because the benefits of laser therapy usually last only a few years. The benefits of surgery, on the other hand, usually last much longer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7832475\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11826?source=see_link\">",
"       Patient information: Age-related vision loss (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24754?source=see_link\">",
"       Patient information: Age-related macular degeneration (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6114?source=see_link\">",
"       Patient information: Cataracts (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/34/11810?source=see_link\">",
"       Patient information: Diabetic retinopathy (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?2/13/2258?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15845 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-87E6A227E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_13_2258=[""].join("\n");
var outline_f2_13_2258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7832343\">",
"      What is glaucoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7832350\">",
"      What are the symptoms of glaucoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7832357\">",
"      Is there a test for glaucoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7832364\">",
"      How is glaucoma treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7832371\">",
"      Which treatment should I have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7832378\">",
"      What if drops don&rsquo;t work for me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7832475\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15845\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/32/23042\">",
"      How glaucoma affects vision",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24754?source=related_link\">",
"      Patient information: Age-related macular degeneration (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11826?source=related_link\">",
"      Patient information: Age-related vision loss (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6114?source=related_link\">",
"      Patient information: Cataracts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/34/11810?source=related_link\">",
"      Patient information: Diabetic retinopathy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_13_2259="Female pelvis - Sagittal view";
var content_f2_13_2259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Female pelvis - Sagittal view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the sagittal view of the female pelvis. Note the rectovaginal septum and the proximity of the uterus and bladder to the rectum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_13_2259=[""].join("\n");
var outline_f2_13_2259=null;
var title_f2_13_2260="Magnesium carbonate, calcium carbonate, and folic acid: Patient drug information";
var content_f2_13_2260=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Magnesium carbonate, calcium carbonate, and folic acid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/33/38421?source=see_link\">",
"     see \"Magnesium carbonate, calcium carbonate, and folic acid: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10118994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      MagneBind&reg; 400 Rx",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10149372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10149374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10149373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2733180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to magnesium carbonate, calcium carbonate, folic acid, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2733182",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High magnesium levels or kidney disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10149378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10149379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10149381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10149376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695847",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take after meals.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10149377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10149382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10149383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12244 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-1A240FD273-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_13_2260=[""].join("\n");
var outline_f2_13_2260=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10118994\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10149372\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10149374\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10149373\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10149378\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10149379\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10149381\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10149376\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10149377\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10149382\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10149383\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/33/38421?source=related_link\">",
"      Magnesium carbonate, calcium carbonate, and folic acid: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_13_2261="Total gastrectomy with reconstruction";
var content_f2_13_2261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Total gastrectomy with reconstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 640px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_13_2261=[""].join("\n");
var outline_f2_13_2261=null;
var title_f2_13_2262="Nonsteroidal antiinflammatory drugs (NSAIDs)";
var content_f2_13_2262=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/13/2262/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/13/2262/contributors\" id=\"au504\">",
"       Daniel H Solomon, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/13/2262/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/13/2262/contributors\" id=\"se4268\">",
"       Daniel E Furst, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/13/2262/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/13/2262/contributors\" id=\"de4792\">",
"       Jerry M Greene, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?2/13/2262?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      NONSTEROIDAL ANTIINFLAMMATORY DRUG OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Nonsteroidal antiinflammatory drugs (NSAIDs) are medications used to relieve pain and to reduce inflammation. They are some of the most commonly used medications in adults. A variety of NSAIDs are available, including at least 20 in the United States and more elsewhere. Many are available as over-the-counter preparations.",
"    </p>",
"    <p>",
"     Because of the wide availability and frequency of use of NSAIDs, it is important to be aware of their proper use, dose, and potential side effects.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CHOOSING A NONSTEROIDAL ANTIINFLAMMATORY DRUG",
"     </span>",
"    </p>",
"    <p>",
"     It can be difficult to know which NSAID is best for a given individual. In addition, a person&rsquo;s response to a particular NSAID is hard to predict. If two people take identical drugs and doses, their individual responses may be considerably different. It is sometimes necessary to try one drug for a few weeks and to then try a different one to find the optimal NSAID.",
"    </p>",
"    <p>",
"     A healthcare provider is the most qualified person to help choose an NSAID, although you can assist in the decision-making process.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      HOW NONSTEROIDAL ANTIINFLAMMATORY DRUGS WORK",
"     </span>",
"    </p>",
"    <p>",
"     NSAIDs work to reduce pain and inflammation by inhibiting enzymes, called cyclooxygenases. By inhibiting cyclooxygenases, NSAIDs help to prevent",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     reduce pain and inflammation. Cyclooxygenase enzyme inhibition is also responsible for many of the side effects of NSAIDs.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      TYPES OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS",
"     </span>",
"    </p>",
"    <p>",
"     There are two main types of NSAIDs, nonselective and selective. The terms nonselective and selective refer to different NSAIDs&rsquo; ability to inhibit specific types of cyclooxygenase (COX) enzymes.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Nonselective NSAIDs &mdash; Nonselective NSAIDs inhibit both COX-1 and COX-2 enzymes to a significant degree.",
"      </li>",
"      <li>",
"       Selective NSAIDs &mdash; Selective NSAIDs inhibit COX-2, an enzyme found at sites of inflammation, more than the type that is normally found in the stomach, blood platelets, and blood vessels (COX-1).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Nonselective NSAIDs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nonselective NSAIDs include drugs commonly available without prescription, such as aspirin, ibuprofen (Advil&reg;, Motrin&reg;, Nuprin&reg;), and naproxen (Aleve&reg;), as well as many prescription-strength NSAIDs.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Selective NSAIDs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Selective NSAIDs (also called COX-2 inhibitors) are as effective in relieving pain and inflammation as nonselective NSAIDs and are less likely to cause gastrointestinal injury. Celecoxib (Celebrex&reg;) is the only selective NSAID currently available in the United States. Other selective NSAIDs that can be found elsewhere in the world include etoricocib (Arcoxia) and lumiracoxib (Prexige).",
"    </p>",
"    <p>",
"     Selective NSAIDs are sometimes recommended for people who have had a peptic ulcer, gastrointestinal bleeding, or gastrointestinal upset when taking nonselective NSAIDs. Selective NSAIDs have",
"     <strong>",
"      less",
"     </strong>",
"     potential to cause ulcers or gastrointestinal bleeding.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Precautions with selective NSAIDs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Rofecoxib (Vioxx&reg;) and valdecoxib (Bextra&reg;) were taken off the market in 2004 when it was discovered that people who took these medications had a slightly increased risk of heart attack and stroke.",
"    </p>",
"    <p>",
"     People with known coronary artery disease (eg, past history of heart attack, angina [chest pain due to narrowed heart arteries], history of a stroke, or narrowed arteries to the brain) and people who are at a higher than average risk for these conditions should avoid using COX-2 inhibitors. Of the nonselective NSAIDs, naproxen may be the safest for people with coronary artery disease, but a clinician should be consulted before use of this or any other NSAID.",
"    </p>",
"    <p>",
"     NSAIDs are generally not recommended for people with kidney disease, heart failure, or cirrhosis or for people who take diuretics. Some patients who are allergic to aspirin may be able to take selective NSAIDs safely, although this should be discussed in advance with a healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Dose of NSAIDs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lower doses of NSAIDs, as recommended for use with nonprescription NSAIDs, are adequate to relieve pain in most people.",
"    </p>",
"    <p>",
"     If the initial dose of NSAIDs does not improve symptoms, a clinician may recommend increasing the dose gradually or switching to another NSAID. People taking one NSAID should not take a second NSAID at the same time. If low doses of NSAIDs are not fully effective, clinicians may recommend using a higher dose of the NSAID on a regular basis for several weeks to improve the antiinflammatory benefits of these drugs.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      NONSTEROIDAL ANTIINFLAMMATORY DRUG SIDE EFFECTS",
"     </span>",
"    </p>",
"    <p>",
"     Most people tolerate NSAIDs without any difficulty. However, side effects can occur. The most common side effects include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Cardiovascular system &mdash; Blood pressure may rise with use of NSAIDs. Control of treated hypertension may be adversely affected by the addition of either selective or nonselective NSAIDs.",
"      </li>",
"      <li>",
"       Gastrointestinal system &mdash; Short-term use of NSAIDs can cause stomach upset (dyspepsia). Long-term use of NSAIDs, especially at high doses, can lead to peptic ulcer disease and bleeding from the stomach. (See",
"       <a class=\"local\" href=\"#H12\">",
"        'Ulcer disease'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Liver toxicity &mdash; Long-term use of NSAIDs, especially at high doses, can rarely harm the liver. Monitoring the liver function with blood tests may be recommended in some cases.",
"      </li>",
"      <li>",
"       Kidney toxicity &mdash; Use of NSAIDs, even for a short period of time, can harm the kidneys. This is especially true in people with underlying kidney disease. The blood pressure and kidney function should be monitored at least once per year but may need to be checked more often, depending on a person&rsquo;s medical conditions. (See",
"       <a class=\"local\" href=\"#H18\">",
"        'Kidney disease'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Ringing in the ears &mdash; Ringing in the ears (tinnitus) is common in people who take high doses of aspirin, although it can also occur in people who take other NSAIDs. The ringing usually resolves when the dose is decreased.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      MEDICAL CONDITIONS AND NONSTEROIDAL ANTIINFLAMMATORY DRUGS",
"     </span>",
"    </p>",
"    <p>",
"     People with some medical problems and those taking various medications are at increased risk of complications related to NSAIDs. Potential complications of NSAIDs include the following:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7264565\">",
"     <span class=\"h2\">",
"      Hypertension",
"     </span>",
"     &nbsp;&mdash;&nbsp;As noted above, the addition of either a selective or a nonselective NSAID to the medications taken by someone with hypertension can result in a loss of blood pressure control. If NSAIDs are required, they should be used at the lowest effective dose and for the shortest duration necessary for the given indication. If chronic use of NSAIDs is anticipated, changes in blood pressure medications may be required.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Cardiovascular disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anyone who is at risk for or who has cardiovascular disease (coronary artery disease) may have a further increase in risk of heart attacks when taking an NSAID. This includes people who have experienced a heart attack, angina (chest pain due to narrowed arteries in the heart), a stroke, or narrowed arteries to the brain. As a result, people who have or who are at risk for coronary artery disease are generally advised to avoid NSAIDs or, if that is not possible, to take the lowest possible dose of NSAID for the shortest possible time.",
"    </p>",
"    <p>",
"     Although aspirin is an NSAID, the recommendation to avoid or limit the use of NSAIDs does",
"     <strong>",
"      NOT",
"     </strong>",
"     apply to people who have been advised to take low-dose aspirin to treat or prevent heart attacks or strokes. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/54/40803?source=see_link\">",
"      \"Patient information: Aspirin and cardiovascular disease (Beyond the Basics)\"",
"     </a>",
"     .) However, the use of any dose of aspirin plus an NSAID is associated with an increased risk of bleeding. There is also some concern that nonselective NSAIDs may reduce the cardiovascular benefits of low-dose aspirin. (See",
"     <a class=\"local\" href=\"#H16\">",
"      'Interaction with other medications'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Ulcer disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Those who have had a stomach or intestinal ulcer are at an increased risk of another ulcer while taking an NSAID. People being treated for ulcers should consult their healthcare provider about the safety of taking NSAIDs or drugs containing aspirin. People over 65 years of age have an increased risk of developing ulcers when taking NSAIDs. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=see_link\">",
"      \"Patient information: Peptic ulcer disease (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Reducing ulcer risk",
"     </span>",
"     &nbsp;&mdash;&nbsp;The risk of developing ulcers can be reduced by taking an anti-ulcer medication in addition to an NSAID. Anti-ulcer agents that reduce gastrointestinal damage from NSAIDs include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Inhibitor of stomach acid production &mdash; High doses of antacid histamine blockers, such as famotidine (Pepcid&reg;), and ordinary doses of the acid production inhibitors, such as omeprazole (Prilosec&reg;) or lansoprazole (Prevacid&reg;), can reduce the risk of developing an ulcer (related to use of an NSAID).",
"      </li>",
"      <li>",
"       Misoprostol &mdash; Misoprostol (Cytotec&reg;) protects the gastrointestinal tract from the effects of NSAIDs and can reduce the risk of gastrointestinal bleeding. Common side effects of misoprostol include diarrhea, abdominal pain, and intestinal cramping.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who have had bleeding from the stomach, upper intestine, or esophagus have an increased risk of recurrent bleeding when taking NSAIDs.",
"    </p>",
"    <p>",
"     People with platelet disorders, such as von Willebrand disease, with abnormal platelet function from uremia, and with a low platelet count (thrombocytopenia) are advised to avoid NSAIDs.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Before surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most clinicians recommend stopping all NSAIDs approximately one week before elective surgery to decrease the risk of excessive bleeding. This usually includes aspirin, ibuprofen, naproxen, and most prescription NSAIDs. Specific instructions regarding NSAIDs and surgery should be discussed with the surgeon and with the clinician who prescribed the NSAID.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Interaction with other medications",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Warfarin and heparin &mdash; People using anticoagulant medications such as warfarin (Coumadin&reg;) or heparin should generally not take NSAIDs or aspirin because of an increased risk of bleeding when both classes of drugs are used. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"        \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"       </a>",
"       .)",
"       <br/>",
"       <br/>",
"       Celecoxib may be safe in such instances but should be used with caution and under the guidance of a clinician.",
"      </li>",
"      <li>",
"       Aspirin &mdash; As noted above, the combination of low-dose aspirin and an NSAID may increase the risk of bleeding. To preserve the benefit of low-dose aspirin for the heart, aspirin should be taken at least two hours before the NSAID. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?39/54/40803?source=see_link\">",
"        \"Patient information: Aspirin and cardiovascular disease (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Phenytoin &mdash; Taking an NSAID and phenytoin (Dilantin&reg;, Phenytek&reg;) can increase the phenytoin level. As a result, people who take phenytoin should have a blood test to monitor the phenytoin level when starting or increasing the dose of an NSAID.",
"      </li>",
"      <li>",
"       Cyclosporine &mdash; People who take cyclosporine (eg, to prevent rejection after an organ transplant or for a rheumatic disease, such as rheumatoid arthritis) should take particular care when taking an NSAID. There is a theoretical risk of kidney damage when cyclosporine and NSAIDs are taken together. To monitor for this complication, blood testing may be recommended.",
"      </li>",
"      <li>",
"       People taking one NSAID should not take a second NSAID at the same time because of the increased risk of side effects.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Fluid retention",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with medical conditions that require diuretics, including heart failure, liver disease, and kidney damage, are at increased risk of developing kidney damage while taking nonselective NSAIDs (eg, ibuprofen) as well as selective NSAIDs (eg, celecoxib [Celebrex&reg;]).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Kidney disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;NSAIDs can worsen kidney function in people whose kidneys are not functioning normally. Most people with chronic kidney disease are advised to avoid all types of NSAIDs. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"      \"Patient information: Chronic kidney disease (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Aspirin allergy",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who have had hives (urticaria) or other symptoms of an allergy to aspirin should generally avoid NSAIDs, unless they have specifically discussed their reaction with a healthcare provider. People with certain types of reactions to one NSAID may be able to take another type safely. It may be necessary to consult with an allergy specialist who has experience with allergic reactions to NSAIDS. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/45/2772?source=see_link\">",
"      \"Patient information: Hives (urticaria) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Aspirin and other NSAIDs may also cause worsening of asthma and related symptoms in some people with these conditions. This is not a true allergy but can be a significant problem for some people, who may need to avoid these medications if this occurs.",
"    </p>",
"    <p>",
"     Celecoxib may be a safe alternative to aspirin in such people but should be used with caution under the supervision of a clinician.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Pregnancy and breastfeeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;NSAIDS are not generally recommended for pregnant women during the third trimester due to an increased risk of complications in the newborn. NSAIDs are safe for use during breastfeeding. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=see_link\">",
"      \"Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      NONSTEROIDAL ANTIINFLAMMATORY DRUG OVERDOSE",
"     </span>",
"    </p>",
"    <p>",
"     Accidentally or intentionally taking a larger than recommended dose of an NSAID does not usually cause serious complications. However, taking large doses of other pain medications may have more serious consequences. For example, overdose with salicylates (eg, aspirin) or acetaminophen (eg, Tylenol&reg;) can be harmful or even fatal.",
"    </p>",
"    <p>",
"     People who accidentally or intentionally take an overdose of any medication should contact their healthcare provider or the Poison Control Hotline (in the United States, 1-800-222-1222). If the person is not breathing or is not conscious, emergency medical attention is needed; this is available in most areas of the United States by calling 911.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784964914\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9137794\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=see_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/23/3443?source=see_link\">",
"      Patient information: Bursitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/32/39425?source=see_link\">",
"      Patient information: von Willebrand disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/7/8307?source=see_link\">",
"      Patient information: Ankylosing spondylitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/9/10386?source=see_link\">",
"      Patient information: Pseudogout (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/32/2563?source=see_link\">",
"      Patient information: Biceps tendinopathy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/47/38642?source=see_link\">",
"      Patient information: Elbow tendinopathy (tennis and golf elbow) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/47/7923?source=see_link\">",
"      Patient information: Separated shoulder (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/11/7347?source=see_link\">",
"      Patient information: Hand pain (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/14/17634?source=see_link\">",
"      Patient information: Achilles tendinopathy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/0/29698?source=see_link\">",
"      Patient information: Reactive arthritis (Reiter syndrome) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/6/23651?source=see_link\">",
"      Patient information: Toxic hepatitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/26/39330?source=see_link\">",
"      Patient information: Clavicle fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/58/36769?source=see_link\">",
"      Patient information: De Quervain&rsquo;s tenosynovitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/15/10482?source=see_link\">",
"      Patient information: Tenosynovitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/53/41810?source=see_link\">",
"      Patient information: Rib fractures in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/33/12819?source=see_link\">",
"      Patient information: Shinbone fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/63/27635?source=see_link\">",
"      Patient information: Vertebral compression fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/4/41026?source=see_link\">",
"      Patient information: Nose fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/61/12242?source=see_link\">",
"      Patient information: Juvenile rheumatoid arthritis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/6/5219?source=see_link\">",
"      Patient information: Boxer&rsquo;s fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/29/3539?source=see_link\">",
"      Patient information: Meniscal tear (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/0/39938?source=see_link\">",
"      Patient information: Muscle strain (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/10/18594?source=see_link\">",
"      Patient information: Patellofemoral pain syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/37/8786?source=see_link\">",
"      Patient information: Metatarsalgia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/22/355?source=see_link\">",
"      Patient information: Toe fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/21/5459?source=see_link\">",
"      Patient information: Pelvic fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/0/15363?source=see_link\">",
"      Patient information: Neck fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/24/29058?source=see_link\">",
"      Patient information: Hemophilia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/56/4994?source=see_link\">",
"      Patient information: Groin strain (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/37/11858?source=see_link\">",
"      Patient information: Chondromalacia patella (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/24/20866?source=see_link\">",
"      Patient information: Erythema nodosum (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/6/11363?source=see_link\">",
"      Patient information: Narcotic pain medicines (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/17/18706?source=see_link\">",
"      Patient information: Chronic hives (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/27/5554?source=see_link\">",
"      Patient information: Iliotibial band syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/52/835?source=see_link\">",
"      Patient information: Psoriatic arthritis in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/6/7267?source=see_link\">",
"      Patient information: Psoriatic arthritis in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/57/25490?source=see_link\">",
"      Patient information: Diffuse idiopathic skeletal hyperostosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/60/15298?source=see_link\">",
"      Patient information: Ehlers-Danlos syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/36/25154?source=see_link\">",
"      Patient information: Microscopic colitis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9138196\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/54/40803?source=see_link\">",
"      Patient information: Aspirin and cardiovascular disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=see_link\">",
"      Patient information: Peptic ulcer disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/45/2772?source=see_link\">",
"      Patient information: Hives (urticaria) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=see_link\">",
"      Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10375?source=see_link\">",
"      COX-2 inhibitors and gastroduodenal toxicity &mdash; major clinical trials",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=see_link\">",
"      NSAIDs (including aspirin): Role in prevention of cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/58/12197?source=see_link\">",
"      NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26947?source=see_link\">",
"      NSAIDs (including aspirin): Treatment of gastroduodenal toxicity",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42674?source=see_link\">",
"      NSAIDs and acetaminophen: Effects on blood pressure and hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26406?source=see_link\">",
"      NSAIDs: Adverse effects on the distal small bowel and colon",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38803?source=see_link\">",
"      NSAIDs: Electrolyte complications",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=see_link\">",
"      NSAIDs: Mechanism of action",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=see_link\">",
"      NSAIDs: Therapeutic use and variability of response in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Academy of Orthopaedic Surgeons",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://orthoinfo.aaos.org/topic.cfm?topic=A00284\">",
"        file://orthoinfo.aaos.org/topic.cfm?topic=A00284",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       United States Food and Drug Administration",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.fda.gov/\">",
"        www.fda.gov",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?2/13/2262/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 20, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?2/13/2262?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2262/abstract/1\">",
"      Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs--differences and similarities. N Engl J Med 1991; 324:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2262/abstract/2\">",
"      Walker JS, Sheather-Reid RB, Carmody JJ, et al. Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis: support for the concept of \"responders\" and \"nonresponders\". Arthritis Rheum 1997; 40:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2262/abstract/3\">",
"      Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2262/abstract/4\">",
"      Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109:2068.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f2_13_2262=[""].join("\n");
var outline_f2_13_2262=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           NONSTEROIDAL ANTIINFLAMMATORY DRUG OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CHOOSING A NONSTEROIDAL ANTIINFLAMMATORY DRUG",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           HOW NONSTEROIDAL ANTIINFLAMMATORY DRUGS WORK",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           TYPES OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           NONSTEROIDAL ANTIINFLAMMATORY DRUG SIDE EFFECTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           MEDICAL CONDITIONS AND NONSTEROIDAL ANTIINFLAMMATORY DRUGS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           NONSTEROIDAL ANTIINFLAMMATORY DRUG OVERDOSE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f2_13_2263="Sinus tachycardia tutorial";
var content_f2_13_2263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1046px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sinus tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 281px; height: 141px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sinus tachycardia is defined as a sinus rhythm with a rate of greater than 100 beats per minute and less than approximately 160 to 180 beats per minute. In this tracing, the rate is about 130 beats per minute.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_13_2263=[""].join("\n");
var outline_f2_13_2263=null;
var title_f2_13_2264="SUNCT and SUNA headache syndromes: Treatment";
var content_f2_13_2264=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   SUNCT and SUNA headache syndromes: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/13/2264/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/13/2264/contributors\">",
"     Manjit S Matharu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/13/2264/contributors\">",
"     Anna S Cohen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/13/2264/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/13/2264/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/13/2264/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/13/2264/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/13/2264/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trigeminal autonomic cephalalgias (TACs) are a group of primary headache disorders characterized by unilateral trigeminal distribution pain that occurs in association with ipsilateral cranial autonomic features [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The TACs include cluster headache, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although SUNCT and SUNA were once considered to be refractory to therapy, beneficial responses with several categories of medications have been reported in small numbers of patients. However, the evidence consists mainly of case reports and small case series.",
"   </p>",
"   <p>",
"    This topic will review the treatment and prognosis of SUNCT and SUNA. The clinical features and diagnosis of these headaches are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28648?source=see_link\">",
"     \"SUNCT and SUNA headache syndromes: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other trigeminal autonomic cephalalgias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=see_link\">",
"     \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25545?source=see_link\">",
"     \"Paroxysmal hemicrania: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27174?source=see_link\">",
"     \"Pathophysiology of the trigeminal autonomic cephalalgias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that SUNCT and SUNA are responsive to acute treatment with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , although supporting evidence comes from a small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, acute treatments used for other trigeminal autonomic cephalalgias, including oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/5,6\">",
"     5,6",
"    </a>",
"    ] and oral and intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/6-13\">",
"     6-13",
"    </a>",
"    ], have not been consistently effective for SUNCT or SUNA. In addition, there is no clear benefit with the use of simple analgesics, combination analgesics, or opioids [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/5,6,14,15\">",
"     5,6,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Lidocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 11 patients with SUNCT and four with SUNA treated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , partial relief to total abolition of symptoms was observed in 14 patients with a recorded response; one patient with SUNCT was lost to follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/4\">",
"     4",
"    </a>",
"    ]. Pain-free periods were variable; the shortest lasted only as long as the duration of the infusion. The longest pain-free periods were three weeks in a patient with chronic SUNCT, 12 weeks in a patient with chronic SUNA, and six months in a patient with episodic SUNCT [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    may be particularly useful for occasional patients with SUNCT who experience acute, severe exacerbations characterized by frequent, easily triggered, high-intensity pain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Such patients may not be able to eat or drink because these actions trigger attacks, and the need for acute intervention is urgent.",
"   </p>",
"   <p>",
"    In addition to rapid amelioration of pain, some patients with a successful response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    infusion are pain-free for weeks after the infusion. This may allow a period of time for either a drug-free interval or for titration and optimization of preventive medications. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Preventive medications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Therefore, we suggest intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    infusion treatment for patients with acute, severe, debilitating attacks of SUNCT or SUNA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Administration and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    (1.5 to 3.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour) is given slowly, with a loading dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over 15 minutes. The total duration of the infusion should not exceed seven days. A response is considered positive if the attacks are mostly or entirely suppressed for the duration of the infusion or longer.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    infusion is associated with the potential for serious adverse events, especially when high doses are utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. These events include cardiac arrhythmias, cognitive impairment, dizziness, nausea, and diarrhea. In addition, we have noticed a particular problem with frequent neuropsychiatric symptoms such as acute depression or paranoia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/21\">",
"     21",
"    </a>",
"    ]. While these adverse events always resolve, they are very disturbing for patient and clinician alike.",
"   </p>",
"   <p>",
"    Continuous ECG monitoring is required during intravenous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , and it is imperative to observe the patient carefully for adverse effects. Intravenous lidocaine should NOT be used in patients with any degree of cardiac conduction system abnormality or heart block who do not have an artificial pacemaker.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREVENTIVE MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously noted, SUNCT and SUNA were once considered to be refractory to treatment. However, data from small open-label studies suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    are moderately effective as preventive therapy for SUNCT and SUNA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lamotrigine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     Lamotrigine",
"    </a>",
"    may be the most effective preventive medication for SUNCT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest study, a case series of 29 patients, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      (up to 400 mg daily) was associated with moderate to good response in 18 patients (62 percent), including 17 of 25 patients with SUNCT and one of four patients with SUNA [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series, a good response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      , defined as a &gt;50 percent reduction in headache frequency",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severity, was seen in 11 of 19 patients overall [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/22\">",
"       22",
"      </a>",
"      ]. The response varied according to the disease course. In the group with episodic",
"      <span class=\"nowrap\">",
"       SUNCT/SUNA,",
"      </span>",
"      a good response to lamotrigine was seen in 9 of 10 patients. However, in the chronic group, defined by attacks occurring for more than one year without remission or with remission lasting less than one month, a good response was obtained in only one of nine patients.",
"     </li>",
"     <li>",
"      In several other case series and case reports of patients with SUNCT,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      (up to 300 mg daily) was reported as effective in 10 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/14,23-26\">",
"       14,23-26",
"      </a>",
"      ], and ineffective in four patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/6,27,28\">",
"       6,27,28",
"      </a>",
"      ]. Lamotrigine (400 mg daily) was also ineffective in a patient with secondary SUNCT related to trigeminal nerve compression [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Dose and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    is 25 mg daily for the first two weeks of treatment, then 50 mg daily for weeks three and four. The dose is thereafter titrated to effect and tolerance. After week four, the daily dose can be increased by 50 mg every one to two weeks. The usual maintenance dose is 200 mg daily given in two divided doses, but total daily doses up to 400 mg given in two divided doses have been used.",
"   </p>",
"   <p>",
"    Systemic side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    include rash and nausea. A benign rash may develop in up to 10 percent of patients during the initial one to two months of therapy and necessitates discontinuation of the drug. The risk of developing a life-threatening rash such as Stevens-Johnson syndrome, toxic epidermal necrolysis, or angioedema is approximately 1 in 1000 adults; this risk is increased in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Topiramate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     Topiramate",
"    </a>",
"    may be useful as a preventive medication for SUNCT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest case series of 22 patients with SUNCT (n = 21) or SUNA (n = 1), treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      (up to 400 mg daily) was associated with a good response in 11 (50 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a blinded crossover trial,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      (100 mg daily in two divided doses) was beneficial for two of five patients with SUNCT, compared with one of five who improved with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Dose and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    is 25 to 50 mg daily; the dose can be increased to 400 mg daily in two divided doses over eight weeks. However, the optimal dose for SUNCT and SUNA is unknown.",
"   </p>",
"   <p>",
"    Weight loss is a common side effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    . Impaired cognition is a reversible side effect observed in a minority of patients taking topiramate, but it is a common reason for discontinuing therapy. Metabolic acidosis and tachypnea may result from renal bicarbonate loss due to the inhibitory effect of topiramate on carbonic anhydrase; patients taking topiramate for prolonged periods may develop kidney stones due to carbonic anhydrase inhibition. Additional side effects include paresthesias, headache, fatigue, dizziness, depression, and mood problems. Acute myopia and secondary angle closure glaucoma are rare side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gabapentin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    may useful as preventive therapy in SUNCT and SUNA.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 27 patients with SUNCT or SUNA, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      (up to 3600 mg daily) was associated with a good response in 13 (48 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An open-label study of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      (up to 900 mg daily) reported complete remission of SUNCT attacks in five of eight patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In other case series and case reports,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      (800 to 2700 mg daily) was associated with complete suppression of SUNCT attacks in three patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/10,31,32\">",
"       10,31,32",
"      </a>",
"      ], but was ineffective in another eight patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/5,6,14\">",
"       5,6,14",
"      </a>",
"      ], and ineffective for one patient with secondary SUNCT associated with compression of the trigeminal nerve [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/8\">",
"       8",
"      </a>",
"      ]. In a patient with SUNA, gabapentin was minimally effective at an unknown dose [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Dose and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although regimens vary, we start with an initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    300 mg the first day, increasing to 300 mg twice a day the second day, and then to 300 mg three times a day on the third day. Thereafter, the dose is increased as needed to 1800 mg a day in three divided doses, although some patients require total doses up to 3600 mg daily. In neuropathic pain conditions, typical maintenance gabapentin doses range from 900 to 2400",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and the drug is usually well tolerated at doses up to 3600 mg daily",
"   </p>",
"   <p>",
"    The major side effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    is sedation. Others include diarrhea, mood swings, ataxia, fatigue, nausea, and dizziness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4615814\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other medications, alone or in combination, have been employed to treat SUNCT and SUNA, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/4-6,8,9,33,34\">",
"     4-6,8,9,33,34",
"    </a>",
"    ], valproate [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/6,12,35,36\">",
"     6,12,35,36",
"    </a>",
"    ], verapamil [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/13,37,38\">",
"     13,37,38",
"    </a>",
"    ], lithium, zonisamide [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/39\">",
"     39",
"    </a>",
"    ], onabotulinumtoxinA (botulinum toxin A) injections [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/40\">",
"     40",
"    </a>",
"    ], and glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/5,9,11,17,41,42\">",
"     5,9,11,17,41,42",
"    </a>",
"    ]. However, none has been consistently effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment choice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the available but limited data, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    as initial preventive medical therapy in patients with frequent or debilitating attacks of SUNCT or SUNA.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     Topiramate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    are reasonable alternatives. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Lamotrigine'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Topiramate'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Gabapentin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several surgical approaches have been attempted for the treatment of SUNCT syndrome. These take the form either of local blockades, invasive procedures involving the trigeminal nerve, or neuromodulatory procedures using superficial nerve and deep brain stimulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Greater occipital nerve blockade and stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nociceptive pathways in the head involve an important interaction between trigeminal and cervical afferents in the trigeminocervical complex [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. This mechanism might be involved in the referral of pain from trigeminal to cervical structures. Thus, either greater occipital nerve blockade or stimulation may play a role in modulating these trigeminocervical connections.",
"   </p>",
"   <p>",
"    Though the mechanism of action of the two treatment modalities is poorly understood, they probably work by completely different mechanisms. Greater occipital nerve blockade reduces afferent traffic along the trigeminal-occipital input, while occipital nerve stimulation increases traffic along this pathway and probably acts by bringing about neuroplastic changes in the pain network.",
"   </p>",
"   <p>",
"    While greater occipital nerve procedures may be beneficial for SUNCT, the evidence is limited.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest reported series, a single greater occipital nerve injection with 2 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      and 80 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      was associated with a good response in five of nine patients with SUNCT or SUNA [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/4\">",
"       4",
"      </a>",
"      ]. In patients responsive to treatment, pain-free times ranged from one week to six months.",
"     </li>",
"     <li>",
"      In another report,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      blockade of the greater occipital nerve was ineffective in two patients with SUNCT [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study, seven patients with medically intractable SUNCT (n = 6) and SUNA (n = 1) were treated with bilateral occipital nerve stimulation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/45\">",
"       45",
"      </a>",
"      ]. At a median follow-up of 24 months, substantial improvement was reported for four patients and moderate improvement for one patient. The procedure was well-tolerated, though one patient developed hemicrania continua one month after implantation and was successfully treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these reports and plausible biologic mechanism of action, we suggest treatment with greater occipital nerve procedures (either blockade or stimulation) for patients who have debilitating SUNCT or SUNA that is refractory to medical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21940101\">",
"    <span class=\"h2\">",
"     Other local blockades",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local blockades of other pericranial nerves (supraorbital, infraorbital, lacrimal), the retrobulbar region, pericranial ganglia (stellate, pterygopalatine, superior cervical) and orbicularis oculi muscles have generally been ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/36,46,47\">",
"     36,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24030013\">",
"    <span class=\"h2\">",
"     Trigeminal microvascular decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small studies, mainly case reports, have suggested that trigeminal microvascular decompression is beneficial for patients with refractory SUNCT who have an abnormal vascular loop in contact with the symptomatic trigeminal nerve at the root entry zone [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/11,28,48-51\">",
"     11,28,48-51",
"    </a>",
"    ]. The largest series reported nine patients with intractable",
"    <span class=\"nowrap\">",
"     SUNCT/SUNA",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/51\">",
"     51",
"    </a>",
"    ]. At 9 to 32 months (mean 22) of follow-up after microvascular decompression, there was complete relief of pain for six of the nine patients, and complications were minimal. While more long-term studies are required, these data suggest that trigeminal microvascular decompression is a viable treatment option in patients with aberrant loops impinging on the ipsilateral trigeminal nerve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Destructive trigeminal nerve procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our experience, invasive, destructive trigeminal nerve procedures are of no value or are harmful in patients with",
"    <span class=\"nowrap\">",
"     SUNCT/SUNA.",
"    </span>",
"    The available evidence is limited to a few patients who were treated with glycerol rhizotomy, gamma knife radiosurgery, or radiofrequency thermocoagulation of the trigeminal nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/6,11,27,51\">",
"     6,11,27,51",
"    </a>",
"    ]. Some authorities recommend that trigeminal surgery be considered only as a last resort, and then with extreme caution, given its uncertain outcomes and the potential for debilitating side effects. However, our view is that destructive procedures have no place in the current management of SUNCT and SUNA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21939939\">",
"    <span class=\"h2\">",
"     Deep brain stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional imaging studies have shown that activation of the posterior hypothalamus is linked to attacks of SUNCT [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/28,52\">",
"     28,52",
"    </a>",
"    ], suggesting that deep brain stimulation might be a therapeutic option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27174?source=see_link\">",
"     \"Pathophysiology of the trigeminal autonomic cephalalgias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are a few case reports of patients with intractable SUNCT who were treated with deep brain stimulation to the posterior hypothalamus and achieved good pain control [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2264/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. In addition, there is evidence suggesting that deep brain stimulation is beneficial for patients with intractable cluster headache. However, diplopia and intracerebral hemorrhage are reported side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3898?source=see_link\">",
"     \"Cluster headache: Acute and preventive treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of deep brain stimulation for patients with SUNCT or SUNA is investigational, and further study is needed to evaluate the utility of this treatment for patients with SUNCT and SUNA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SUNCT and SUNA were once considered to be refractory to therapy, but appear to be responsive to acute treatment with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      . Acute treatments used for other trigeminal autonomic cephalalgias, including oxygen and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      , have not been consistently effective for SUNCT or SUNA. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute, severe, debilitating attacks of SUNCT or SUNA, we suggest acute treatment with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      infusion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Continuous ECG monitoring is required during intravenous lidocaine administration, along with close observation for adverse effects. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Lidocaine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data from small open-label studies suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      are moderately effective as preventive therapy Data from small open-label studies suggest that lamotrigine, topiramate, and gabapentin are moderately effective as preventive therapy for SUNCT and SUNA. A variety of other medications, alone or in combination, have also been employed to treat SUNCT and SUNA, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , valproate,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , and glucocorticoids, though none has been consistently effective. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Preventive medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with frequent or debilitating attacks of SUNCT or SUNA, we suggest initial preventive medical therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients who do not respond to or tolerate lamotrigine, reasonable alternative preventive treatments are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Lamotrigine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Topiramate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Gabapentin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with frequent or debilitating attacks of SUNCT or SUNA who are refractory to medical therapy, we suggest greater occipital nerve procedures with either blockade using 2 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      and 80 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , or occipital nerve stimulation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Greater occipital nerve blockade and stimulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/1\">",
"      Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain 1997; 120 ( Pt 1):193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/2\">",
"      Goadsby PJ. Trigeminal autonomic cephalalgias. Pathophysiology and classification. Rev Neurol (Paris) 2005; 161:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/3\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/4\">",
"      Cohen AS. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing. Cephalalgia 2007; 27:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/5\">",
"      Matharu MS, Cohen AS, Boes CJ, Goadsby PJ. Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome: a review. Curr Pain Headache Rep 2003; 7:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/6\">",
"      Matharu MS, Cohen AS, Goadsby PJ. SUNCT syndrome responsive to intravenous lidocaine. Cephalalgia 2004; 24:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/7\">",
"      Prakash KM, Lo YL. SUNCT syndrome in association with persistent Horner syndrome in a Chinese patient. Headache 2004; 44:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/8\">",
"      K&ouml;seoglu E, Karaman Y, K&uuml;c&uuml;k S, Arman F. SUNCT syndrome associated with compression of trigeminal nerve. Cephalalgia 2005; 25:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/9\">",
"      Rossi P, Cesarino F, Faroni J, et al. SUNCT syndrome successfully treated with topiramate: case reports. Cephalalgia 2003; 23:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/10\">",
"      Hunt CH, Dodick DW, Bosch EP. SUNCT responsive to gabapentin. Headache 2002; 42:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/11\">",
"      Gardella L, Viruega A, Rojas H, Nagel J. A case of a patient with SUNCT syndrome treated with Jannetta procedure. Cephalalgia 2001; 21:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/12\">",
"      Volcy M, Tepper SJ, Rapoport AM, et al. Short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA)--a case report. Cephalalgia 2005; 25:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/13\">",
"      Narbone MC, Gangemi S, Abbate M. A case of SUNCT syndrome responsive to verapamil. Cephalalgia 2005; 25:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/14\">",
"      Malik K, Rizvi S, Vaillancourt PD. The SUNCT syndrome: successfully treated with lamotrigine. Pain Med 2002; 3:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/15\">",
"      Putzki N, Nirkko A, Diener HC. Trigeminal autonomic cephalalgias: a case of post-traumatic SUNCT syndrome? Cephalalgia 2005; 25:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/16\">",
"      Pareja JA, Caballero V, Sjaastad O. SUNCT syndrome. Statuslike pattern. Headache 1996; 36:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/17\">",
"      Montes E, Alberca R, Lozano P, et al. Statuslike SUNCT in two young women. Headache 2001; 41:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/18\">",
"      Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991; 41:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/19\">",
"      Ferrante FM, Paggioli J, Cherukuri S, Arthur GR. The analgesic response to intravenous lidocaine in the treatment of neuropathic pain. Anesth Analg 1996; 82:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/20\">",
"      Wallace MS, Dyck JB, Rossi SS, Yaksh TL. Computer-controlled lidocaine infusion for the evaluation of neuropathic pain after peripheral nerve injury. Pain 1996; 66:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/21\">",
"      Gil-Gouveia R, Goadsby PJ. Neuropsychiatric side-effects of lidocaine: examples from the treatment of headache and a review. Cephalalgia 2009; 29:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/22\">",
"      Williams MH, Broadley SA. SUNCT and SUNA: clinical features and medical treatment. J Clin Neurosci 2008; 15:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/23\">",
"      D'Andrea G, Granella F, Cadaldini M. Possible usefulness of lamotrigine in the treatment of SUNCT syndrome. Neurology 1999; 53:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/24\">",
"      Leone M, Rigamonti A, Usai S, et al. Two new SUNCT cases responsive to lamotrigine. Cephalalgia 2000; 20:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/25\">",
"      D'Andrea G, Granella F, Ghiotto N, Nappi G. Lamotrigine in the treatment of SUNCT syndrome. Neurology 2001; 57:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/26\">",
"      Gutierrez-Garcia JM. SUNCT syndrome responsive to lamotrigine. Headache 2002; 42:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/27\">",
"      Black DF, Dodick DW. Two cases of medically and surgically intractable SUNCT: a reason for caution and an argument for a central mechanism. Cephalalgia 2002; 22:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/28\">",
"      Sprenger T, Valet M, Platzer S, et al. SUNCT: bilateral hypothalamic activation during headache attacks and resolving of symptoms after trigeminal decompression. Pain 2005; 113:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/29\">",
"      Cohen AS, Matharu MS, Goadsby PJ. Double-blind placebo-controlled trial of topiramate in SUNCT. Cephalalgia 2007; 27:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/30\">",
"      Etemadifar M, Maghzi AH, Ghasemi M, et al. Efficacy of gabapentin in the treatment of SUNCT syndrome. Cephalalgia 2008; 28:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/31\">",
"      Graff-Radford SB. SUNCT syndrome responsive to gabapentin (Neurontin). Cephalalgia 2000; 20:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/32\">",
"      Porta-Etessam J, Martinez-Salio A, Berbel A, Benito-Leon J. Gabapentin (neuronetin) in the treatment of SUNCT syndrome. Cephalalgia 2002; 22:249; author reply 249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/33\">",
"      Cohen AS, Matharu MS, Goadsby PJ. SUNCT syndrome in the elderly. Cephalalgia 2004; 24:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/34\">",
"      Gantenbein AR, Goadsby PJ. Familial SUNCT. Cephalalgia 2005; 25:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/35\">",
"      Sesso RM. SUNCT syndrome or trigeminal neuralgia with lacrimation and conjunctival injection? Cephalalgia 2001; 21:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/36\">",
"      Pareja JA, Kruszewski P, Sjaastad O. SUNCT syndrome: trials of drugs and anesthetic blockades. Headache 1995; 35:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/37\">",
"      Jim&eacute;nez-Huete A, Franch O, Pareja JA. SUNCT syndrome: priming of symptomatic periods and worsening of symptoms by treatment with calcium channel blockers. Cephalalgia 2002; 22:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/38\">",
"      May A, Bahra A, B&uuml;chel C, et al. Functional magnetic resonance imaging in spontaneous attacks of SUNCT: short-lasting neuralgiform headache with conjunctival injection and tearing. Ann Neurol 1999; 46:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/39\">",
"      Ikawa M, Imai N, Manaka S. A case of SUNCT syndrome responsive to zonisamide. Cephalalgia 2011; 31:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/40\">",
"      Zabalza RJ. Sustained response to botulinum toxin in SUNCT syndrome. Cephalalgia 2012; 32:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/41\">",
"      Calvo JF, Bruera OC, de Lourdes Figuerola M, et al. SUNCT syndrome: clinical and 12-year follow-up case report. Cephalalgia 2004; 24:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/42\">",
"      Trauninger A, Alkonyi B, Kov&aacute;cs N, et al. Methylprednisolone therapy for short-term prevention of SUNCT syndrome. Cephalalgia 2010; 30:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/43\">",
"      Goadsby PJ. Migraine pathophysiology. Headache 2005; 45 Suppl 1:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/44\">",
"      Goadsby PJ, Bartsch T, Dodick DW. Occipital nerve stimulation for headache: mechanisms and efficacy. Headache 2008; 48:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/45\">",
"      Matharu M, Watkins L, Shanahan P. POH04 Treatment of medically intractable SUNCT and SUNA with occipital nerve stimulation. J Neurol Neurosurg Psychiatry 2010; 81:e51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/46\">",
"      Sabatowski R, Huber M, Meuser T, Radbruch L. SUNCT syndrome: a treatment option with local opioid blockade of the superior cervical ganglion? A case report. Cephalalgia 2001; 21:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/47\">",
"      Hannerz J, Linderoth B. Neurosurgical treatment of short-lasting, unilateral, neuralgiform hemicrania with conjunctival injection and tearing. Br J Neurosurg 2002; 16:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/48\">",
"      Lagares A, G&oacute;mez PA, P&eacute;rez-Nu&ntilde;ez A, et al. Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome treated with microvascular decompression of the trigeminal nerve: case report. Neurosurgery 2005; 56:E413; discussion E413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/49\">",
"      Irimia P, Gonz&aacute;lez-Redondo R, Dom&iacute;nguez PD, et al. Microvascular decompression may be effective for refractory SUNCT regardless of symptom duration. Cephalalgia 2010; 30:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/50\">",
"      Guerreiro R, Casimiro M, Lopes D, et al. Video NeuroImage: symptomatic SUNCT syndrome cured after trigeminal neurovascular contact surgical decompression. Neurology 2009; 72:e37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/51\">",
"      Williams M, Bazina R, Tan L, et al. Microvascular decompression of the trigeminal nerve in the treatment of SUNCT and SUNA. J Neurol Neurosurg Psychiatry 2010; 81:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/52\">",
"      May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 1999; 19:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/53\">",
"      Leone M, Franzini A, D'Andrea G, et al. Deep brain stimulation to relieve drug-resistant SUNCT. Ann Neurol 2005; 57:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2264/abstract/54\">",
"      Lyons MK, Dodick DW, Evidente VG. Responsiveness of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing to hypothalamic deep brain stimulation. J Neurosurg 2009; 110:279.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3338 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_13_2264=[""].join("\n");
var outline_f2_13_2264=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Lidocaine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Administration and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREVENTIVE MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lamotrigine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Dose and side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Topiramate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Dose and side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gabapentin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Dose and side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4615814\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment choice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Greater occipital nerve blockade and stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21940101\">",
"      Other local blockades",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24030013\">",
"      Trigeminal microvascular decompression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Destructive trigeminal nerve procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21939939\">",
"      Deep brain stimulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3898?source=related_link\">",
"      Cluster headache: Acute and preventive treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=related_link\">",
"      Cluster headache: Epidemiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25545?source=related_link\">",
"      Paroxysmal hemicrania: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27174?source=related_link\">",
"      Pathophysiology of the trigeminal autonomic cephalalgias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28648?source=related_link\">",
"      SUNCT and SUNA headache syndromes: Clinical features and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_13_2265="Rheumatic manifestations of hereditary hemochromatosis";
var content_f2_13_2265=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rheumatic manifestations of hereditary hemochromatosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/13/2265/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/13/2265/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/13/2265/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/13/2265/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/13/2265/contributors\">",
"     Michael A Becker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/13/2265/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/13/2265/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/13/2265/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary hemochromatosis (HH), also called genetic hemochromatosis, is a genetically determined disorder in which mutations in the HFE gene or the TFR2 gene cause increased intestinal iron absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Details of the interaction between the transferrin receptor and HFE gene product and of the role of the TFR2 gene are still uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link\">",
"     \"Genetics of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of this disorder (and of other forms of iron overload) are related to iron deposition in tissues, such as the liver, pancreas, and heart. Approximately one-half of patients with HH, if untreated, eventually develop arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"     \"Clinical manifestations of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will focus on the major rheumatic manifestations of hemochromatosis: arthropathy and osteoporosis. The major genetic, clinical, diagnostic, and therapeutic features of hereditary hemochromatosis are discussed separately. (See appropriate topic reviews.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF ARTHRITIS IN HEMOCHROMATOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying cause of arthritis among patients with HH is unknown. Iron deposition and defects in cartilage and in immunologic function have been implicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Iron deposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron deposition within joints may trigger a number of pathologic events, such as free radical generation and crystal deposition. In some cases, the generation of free radicals may cause changes in immunoglobulin carbohydrate composition that promote immune complex formation and inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. These alterations are superimposed upon the joint changes resulting from calcium pyrophosphate deposition.",
"   </p>",
"   <p>",
"    The presence of ferric salts within joints may enhance crystal deposition by promoting crystal formation and by inhibiting crystal removal [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. As an example, the clearance rate of calcium pyrophosphate dihydrate (CPPD) crystals from joints was measured in a rabbit model of iron deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/17\">",
"     17",
"    </a>",
"    ]. Synovial hemosiderosis due to the injection of blood into the knee significantly reduced the clearance of CPPD crystals, thereby suggesting that intracellular pyrophosphates are inhibited by iron.",
"   </p>",
"   <p>",
"    However, a number of observations are inconsistent with a role for iron deposition in causing arthritis in HH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No correlation exists between the extent of iron deposition and the histological and radiological changes in the joint.",
"     </li>",
"     <li>",
"      The removal of systemic iron has little effect upon arthritic symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The arthritis of HH may not be specific for iron overload [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/18\">",
"       18",
"      </a>",
"      ]. Although increased deposition of iron in the synovial tissue is observed in a variety of other diseases (such as rheumatoid arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/12,18\">",
"       12,18",
"      </a>",
"      ], degenerative arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/10\">",
"       10",
"      </a>",
"      ], pigmented villonodular synovitis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/12,19\">",
"       12,19",
"      </a>",
"      ], hemophilia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/20\">",
"       20",
"      </a>",
"      ], and hemarthrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/21\">",
"       21",
"      </a>",
"      ]), the pathologic findings in the joints of patients with these disorders differ from those observed in HH. In addition, the arthropathy in HH is clinically similar to that observed in diseases not associated with iron deposition, including CPPD deposition disease [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/22-25\">",
"       22-25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cartilage defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;An additional metabolic abnormality, independent of the disorder of iron metabolism, may be responsible for an alteration in cartilage matrix among patients with HH, thereby causing arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. This mechanism is consistent with the observation that the arthritis of HH is clinically similar to that of other metabolic disorders, such as hyperparathyroidism, ochronosis, and Wilson's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased levels of fragments of parathyroid hormone (PTH) occur in HH and may play a role in the osteoarticular manifestations of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/29\">",
"     29",
"    </a>",
"    ]. However, similarly elevated levels of PTH fragments occur in calcium pyrophosphate deposition disease (CPPD), in the absence of HH [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/30\">",
"     30",
"    </a>",
"    ]. This suggests that the two disorders may share some pathophysiologic mechanisms, in addition to chondrocalcinosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Immunologic defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in immune cell function may also contribute to the development of arthritis in HH. A variety of immunologic abnormalities have been observed among patients with secondary iron overload and parenteral iron overload, but it is unclear whether such dysfunction is primary or results from the effects of immune modifying treatments, such as blood transfusions and splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\"",
"    </a>",
"    .) Reported abnormalities include a decrease in superoxide anion production from neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], a reduction in CD4, and both expansion of and decrease in CD8 positive T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/33-36\">",
"     33-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cytotoxic CD8+ T-cells show reduced activity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/37\">",
"     37",
"    </a>",
"    ] and use a skewed T-cell receptor repertoire [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/38\">",
"     38",
"    </a>",
"    ]. It is not clear whether these changes are due to the altered HFE protein or to other pathological changes of HH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial tissue in HH is brown because of iron deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/18,27\">",
"     18,27",
"    </a>",
"    ]. Abnormal amounts of iron deposits, little or no signs of synovial inflammation, and calcium pyrophosphate dihydrate deposition are characteristic findings upon microscopic examination. Synovial histology in HH arthropathy resembles osteoarthritis (OA). However, neutrophil invasion is significantly increased, especially in joints with iron deposition, and may stimulate the production of matrix enzymes, causing cartilage degradation and rapidly progressive articular damage [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/39\">",
"     39",
"    </a>",
"    ]. Other common findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The intimal and phagocytic cells may contain iron in association with intimal cell hypoplasia and villus formation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cartilage may be stripped from the subchondral bone at the level of the tide-mark in the calcified cartilage zone. This finding, which may be specific to HH, is caused by increased susceptibility to shearing forces at the bone cartilage interface (",
"      <a class=\"graphic graphic_picture graphicRef78124 \" href=\"UTD.htm?25/63/26623\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Apatite and CPPD crystals may occur together with iron deposits [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/11\">",
"       11",
"      </a>",
"      ], but there is no spatial relationship. In addition, crystals can be found in the absence of iron deposits. CPPD crystals in intervertebral discs are found in the outer and peripheral layers of the annulus fibrosis and of the ligamentum flavum and in association with microfissure formation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chronic inflammatory cell infiltration is uncommon. Electron microscopy reveals that iron is predominantly found in the lining cells rich in rough endoplasmic reticulum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of arthritis in HH cannot be predicted by the level of serum iron or by other measures of iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/42\">",
"     42",
"    </a>",
"    ]. Although high serum transferrin saturation values correspond with the presence of arthritis, a high value may only represent an extended duration of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/43\">",
"     43",
"    </a>",
"    ]. However, the association of arthropathy, homozygosity for C282Y, and increased serum ferritin concentrations at the time of diagnosis suggest that iron load is likely to be a major determinant of arthropathy in HH and to be more important than occupational factors. In one study, arthropathy was found in 24 percent of patients with definite or probable HH [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/44\">",
"     44",
"    </a>",
"    ]. Joint involvement has not been mentioned in reports of juvenile onset HH [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although arthritis may be the presenting symptom of HH [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/48,49\">",
"     48,49",
"    </a>",
"    ], rheumatic symptoms",
"    <strong>",
"     can",
"    </strong>",
"    occur after the diagnosis has been made. Symptoms are more severe in those over 50 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/9,50\">",
"     9,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The arthropathy of HH may significantly affect the quality of life. One study of 50 consecutive patients, for example, found that the manifestations of arthritis, as compared with those of diabetes and cirrhosis, was the single most prominent factor affecting the patient's perception of quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The arthritic manifestations of HH are diverse [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common presenting symptom is twinges of pain upon flexing the small joints of the hand, particularly the second and third metacarpophalangeal joints; joint inflammation is typically minimal [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/9,54\">",
"       9,54",
"      </a>",
"      ]. However, an acute presentation can also occur [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/55\">",
"       55",
"      </a>",
"      ]. Arthritis may then progress to involve the large joints, particularly the hips, knees, and shoulders; such involvement may occasionally cause severe disability, requiring surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The distribution of joint involvement may resemble rheumatoid arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/56\">",
"       56",
"      </a>",
"      ]. Acute attacks of inflammation with bilateral destruction of the metacarpophalangeal joints can occur, and reduced flexion at the metacarpophalangeal joints has been noted. A rheumatoid flare may be mimicked by acute attacks of synovitis, probably resulting from calcium pyrophosphate dihydrate deposition [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/9,50\">",
"       9,50",
"      </a>",
"      ]. Ulnar deviation, a common finding in rheumatoid arthritis, has not been reported in HH.",
"     </li>",
"     <li>",
"      Bony swelling may develop and may superficially resemble osteoarthritis.",
"     </li>",
"     <li>",
"      Chondrocalcinosis (which refers to radiographic calcification in hyaline",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibrocartilage) is common and is usually asymptomatic (see below).",
"     </li>",
"     <li>",
"      In contrast to the typical findings described above, some patients have only mild arthralgia at night or upon awakening [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one study that reviewed the clinical features of arthropathy in 25 patients with HH, clinical arthritis was observed in 16 patients (64 percent), and an additional two asymptomatic patients had radiographic evidence of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/57\">",
"     57",
"    </a>",
"    ]. The most common sites of involvement were the wrists and metacarpophalangeal joints, and severe involvement of the hip occurred in six patients. Nine patients had chondrocalcinosis (36 percent), which was most commonly asymptomatic.",
"   </p>",
"   <p>",
"    A case-control study strongly suggested an increased prevalence of both osteoarthritis (OA) and osteoporosis (OP) in patients with HH compared with controls (51 versus 29 percent, adjusted odds ratio [aOR] 2.5, 95% CI 1.8-3.6, and 23 versus 5 percent, aOR 7.3, 95% CI 3.2-17.0, respectively). Interestingly, among the patients with HH, the findings of OA, OP, a hip prosthesis, and wrist and vertebral fractures were more likely in those with more severe iron overload (&gt;1000",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    at time of diagnosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study also found that HH was a risk factor for joint replacement surgery because of severe secondary osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The articular features of HH are often misdiagnosed. Determination of the HFE genotype is clinically useful in patients with arthritis of unknown origin to allow early diagnosis of hemochromatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis among patients with HH is characterized by the following patterns of radiographic involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/22,61\">",
"     22,61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolated chondrocalcinosis",
"     </li>",
"     <li>",
"      Hypertrophic osteoarthritis, which is indistinguishable radiologically from calcium pyrophosphate-associated arthropathy",
"     </li>",
"     <li>",
"      Disease specific changes which include subchondral radiolucency of the femoral head (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50704 \" href=\"UTD.htm?3/20/3406\">",
"       image 1",
"      </a>",
"      ), hook-like osteophytes on the metacarpal heads, and a degenerative predilection for the metacarpophalangeal joint rather than the scapholunate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Small cysts of approximately 1 to 3 mm in diameter affecting the metacarpal heads may be observed early in the course of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/9,50\">",
"     9,50",
"    </a>",
"    ]. In addition, joint surfaces may become roughened and irregular, thereby resulting in the destruction of the articular surface (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78740 graphicRef51733 \" href=\"UTD.htm?41/51/42801\">",
"     image 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/27\">",
"     27",
"    </a>",
"    ]. Radiographic evidence of sclerosis and joint narrowing may also be observed.",
"   </p>",
"   <p>",
"    A feasible and reliable radiological assessment tool for the evaluation of hemochromatosis arthropathy has been validated, and an atlas of characteristic radiographic features has been provided [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chondrocalcinosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chondrocalcinosis due to calcium pyrophosphate dihydrate deposition is present in approximately two-thirds of patients with HH [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/9\">",
"     9",
"    </a>",
"    ]. As the disorder progresses, the incidence and severity of CPPD deposition increases. The knees and wrists are most frequently involved, while the hips, symphysis pubis, and spine may also be affected (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77869 \" href=\"UTD.htm?7/52/8015\">",
"     image 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link\">",
"     \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    .) Calcification of the intervertebral discs may radiographically resemble ankylosing spondylitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/41\">",
"     41",
"    </a>",
"    ]. In addition, the Achilles tendon and plantar fascia may be other sites of soft tissue calcification.",
"   </p>",
"   <p>",
"    CPPD deposition is not related to age or to the amount of iron deposited. Radiologic progression of CPPD deposition (and arthritis) does not decrease or disappear with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are distinct radiographic differences between the arthropathy of HH and primary CPPD disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/61\">",
"     61",
"    </a>",
"    ]. HH is distinguished by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      More prevalent narrowing of the metacarpophalangeal joints, including those in the fourth and fifth digits",
"     </li>",
"     <li>",
"      Peculiar hook-like osteophytes on the radial aspect of the metacarpal heads",
"     </li>",
"     <li>",
"      Less prevalent separation of the scaphoid and the lunate bones",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These radiographic differences indicate that the arthropathy of HH is related to other factors in addition to the presence of CPPD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6375?source=see_link\">",
"     \"Pathogenesis and etiology of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A reliable radiological assessment tool for the evaluation of hemochromatosis arthropathy has been validated and an atlas of characteristic radiographic features has been compiled and published [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The methods used to establish the presence of iron overload include serum iron studies, various radiologic techniques, liver biopsy, and assessment of the response to phlebotomy or chelation therapy. These approaches and HFE gene testing are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HFE gene discovery has simplified the diagnosis of HH and has modified our understanding of clinical presentation and epidemiology [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/63\">",
"     63",
"    </a>",
"    ]. Screening of newborns for HH associated HFE gene mutations, if widely adopted, could lead to identification of affected presymptomatic adults with HH, a technique referred to as reverse cascade screening [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HH is suggested by increases in transferrin saturation and the serum ferritin concentration; it is confirmed by liver biopsy or specific genetic testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    .) In general, the differential diagnosis includes any cause of an inflammatory arthropathy. Most commonly, the principal arthritic disorders which must be distinguished from the arthropathy of HH are primary CPPD disease and rheumatoid arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     CPPD disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, unique radiographic differences may be used to distinguish primary CPPD disease from the disorder associated with HH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link\">",
"     \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distribution of joint involvement and acute attacks of synovitis in HH may be similar to that seen in patients with rheumatoid arthritis (RA). Patients with HH do not have the characteristic small joint changes found in rheumatoid arthritis (eg, swan neck deformity) and do not typically meet the criteria for the diagnosis of rheumatoid arthritis. Although rheumatoid factor testing may occasionally be positive in HH arthropathy, anti-CCP antibodies are rarely present and may be helpful in distinguishing the arthropathy of HH from RA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical osteoarthritis (OA) of joints that have a propensity to be involved in HH arthritis (eg, index and middle finger MCP joints) may be increased in prevalence among patients who are heterozygous for HFE mutations and who are not iron overloaded [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/66\">",
"     66",
"    </a>",
"    ]. A case-controlled study has demonstrated a significant association between HH and OA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/58\">",
"     58",
"    </a>",
"    ], and a significant association was also observed between HFE gene mutations and primary OA in the ankle [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=see_link\">",
"     \"Diagnosis and classification of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of HH by phlebotomy generally has little effect upon the clinical, radiologic, or histologic progression of the arthropathy. In one series, for example, only 20 percent of 129 patients noted improvement in joint symptoms after phlebotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     Deferoxamine",
"    </a>",
"    is an effective alternative therapy for iron overload when phlebotomy is not possible [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/69\">",
"     69",
"    </a>",
"    ], but it is unknown whether iron chelation with this agent will have any impact on the progression of the arthropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=see_link\">",
"     \"Treatment of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Future therapies for the iron overload of HH may consist of oral iron-binding agents capable of preventing dietary iron absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/70\">",
"     70",
"    </a>",
"    ]. The characterization of specific iron transporters such as the divalent metallic transporter and ferroportin may hold promise for the development of &ldquo;smart&rdquo; compounds capable of blocking iron transport [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional treatment options for arthritis may include the use of analgesics, NSAIDs, intraarticular glucocorticoids, and short-term glucocorticoids.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    may be effective in patients with recurrent pseudogout [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Novel therapies being developed include the rapid and sustained action of a single dose of hepcidin as an agent for the prevention of iron accumulation and enterocyte targeting with a gene coding for a short antisense against iron transport blocks enterocyte iron uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OSTEOPOROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the arthropathy, a significant decrease in bone density is frequently observed among patients with HH and other forms of iron overload, particularly those with concurrent hypogonadism [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/27,74-76\">",
"     27,74-76",
"    </a>",
"    ]. The incidence of osteoporosis varies from 25 to about 50 percent in HH [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/26,27,50,58,74\">",
"     26,27,50,58,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteoporosis is usually clinically asymptomatic and may be localized to the hands. Bone mass is lower in patients with hypogonadism, but osteoporosis can also be seen in eugonadal subjects indicating that other factors also must contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcium kinetic studies suggest a deficiency in calcium absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/27\">",
"     27",
"    </a>",
"    ]. Serum concentrations of calcium, phosphorus, and alkaline phosphatase are usually normal. Osteoblastic function is significantly greater in phlebotomized than in non-phlebotomized patients, although the trabecular bone volumes of these two groups were similar in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone densitometry should be carried out as there were significant bone loss in HFE-gene related hemochromatosis in the absence of hypogonadism or cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ASEPTIC PROSTHETIC LOOSENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who require primary total hip arthroplasty and who are homozygous for the C282Y mutation of the HFE gene have an increased risk of developing aseptic loosening, leading to revision THA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2265/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening and targeted testing are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12535?source=see_link\">",
"     \"Screening for hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5295293\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hereditary hemochromatosis (HH) is a genetically determined disorder in which mutations in the HFE gene or the TFR2 gene cause increased intestinal iron absorption. The clinical manifestations are related to iron deposition in tissues, such as the liver, pancreas, and heart. Approximately one-half of patients with HH, if untreated, eventually develop arthritis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Iron deposition within joints may trigger a number of pathologic events, such as free radical generation and the deposition of crystals, including calcium pyrophosphate. In some cases, the generation of free radicals may cause changes in immunoglobulin carbohydrate composition that promote immune complex formation and inflammation. The role of iron deposition in directly causing arthritis in HH is uncertain. Alterations in the cartilage matrix and increased levels of fragments of parathyroid hormone may also play a role, as may abnormalities in immune cell function resulting from the effects of either iron overload or treatment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis of arthritis in hemochromatosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Synovial tissue in HH is brown because of iron deposition. Abnormal amounts of iron deposits, few or no signs of synovial inflammation, and calcium pyrophosphate dihydrate (CPPD) deposition are characteristic findings upon microscopic examination. Neutrophil invasion of the synovium may be seen, particularly in joints with increased iron deposition. Apatite and CPPD crystals may occur together with iron deposits, but there is no spatial relationship. In addition, crystals can be found in the absence of iron deposits. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of arthritis in HH cannot be predicted by measures of iron overload. High serum transferrin saturation values correspond with the presence of arthritis, and musculoskeletal morbidity corresponds with the severity of iron overload. However, a high value may only represent an extended duration of disease. Arthritis may be the presenting symptom of HH, but rheumatic symptoms can occur after the diagnosis has been made. The metacarpophalangeal (MCP) joints, especially the second and third MCP, and the wrists are commonly affected. Other involved joints frequently include the hips, knees, and shoulders and may occasionally cause severe disability requiring surgery. Acute arthritis flares related to CPPD may occur, but, while chondrocalcinosis is common, it is usually asymptomatic. Bilateral destruction of the MCP joints and reduced flexion at the metacarpophalangeal joints have been noted. Some patients experience only mild arthralgia at night or upon awakening. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Arthritis among patients with HH is characterized radiographically by several patterns, including isolated chondrocalcinosis; hypertrophic osteoarthritis, which is indistinguishable radiologically from CPPD-associated arthropathy; and disease specific changes which include subchondral radiolucency of the femoral head, hook-like osteophytes on the metacarpal heads, and a degenerative predilection for the metacarpophalangeal joint rather than the scapholunate. Chondrocalcinosis most frequently involves the knees and wrists, while the hips, symphysis pubis, and spine may also be affected. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Radiographic manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Chondrocalcinosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of HH is suggested by increases in transferrin saturation and the serum ferritin concentration; it is confirmed by liver biopsy or specific genetic testing. In general, the differential diagnosis includes any cause of an inflammatory arthropathy. Most commonly, the principal arthritic disorders which must be distinguished from the arthropathy of HH are primary CPPD disease and rheumatoid arthritis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"       \"Pathophysiology and diagnosis of iron overload syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of HH by phlebotomy generally has little effect upon the clinical, radiologic, or histologic progression of the arthropathy. It is unknown whether",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      , an effective alternative therapy for iron overload when phlebotomy is not possible, will have any impact on the progression of the arthropathy. Treatment options for arthritis include analgesics, NSAIDs, intraarticular glucocorticoids, and short-term glucocorticoids.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"      may be effective in patients with recurrent pseudogout. Patients who require primary total hip arthroplasty may be at increased risk of aseptic loosening of the prosthetic. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Aseptic prosthetic loosening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A significant decrease in bone density is frequently observed among patients with HH and other forms of iron overload, particularly those with concurrent hypogonadism, and bone densitometry should be performed in patients with HH. The incidence varies from 25 to about 50 percent in HH. Bone mass is lower in patients with hypogonadism, but osteoporosis can also be seen in eugonadal subjects. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Osteoporosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/1\">",
"      Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/2\">",
"      Jouanolle AM, Gandon G, J&eacute;z&eacute;quel P, et al. Haemochromatosis and HLA-H. Nat Genet 1996; 14:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/3\">",
"      Bodmer JG, Parham P, Albert ED, Marsh SG. Putting a hold on \"HLA-H'. The WHO Nomenclature Committee for Factors of the HLA System. Nat Genet 1997; 15:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/4\">",
"      Camaschella C, Roetto A, Cal&igrave; A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/5\">",
"      Feder JN, Penny DM, Irrinki A, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A 1998; 95:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/6\">",
"      Roy CN, Penny DM, Feder JN, Enns CA. The hereditary hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells. J Biol Chem 1999; 274:9022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/7\">",
"      Salter-Cid L, Brunmark A, Li Y, et al. Transferrin receptor is negatively modulated by the hemochromatosis protein HFE: implications for cellular iron homeostasis. Proc Natl Acad Sci U S A 1999; 96:5434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/8\">",
"      Dorfmann H, Solnica J, Di Menza C, de S&egrave;ze S. [The arthropathies of hemochromatosis. Results of a prospective study of 54 patients]. Sem Hop 1969; 45:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/9\">",
"      Dymock IW, Hamilton EB, Laws JW, Williams R. Arthropathy of haemochromatosis. Clinical and radiological analysis of 63 patients with iron overload. Ann Rheum Dis 1970; 29:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/10\">",
"      Schumacher HR Jr. Ultrastructural characteristics of the synovial membrane in idiopathic haemochromatosis. Ann Rheum Dis 1972; 31:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/11\">",
"      Schumacher HR. Articular cartilage in the degenerative arthropathy of hemochromatosis. Arthritis Rheum 1982; 25:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/12\">",
"      Muirden KD, Senator GB. Iron in the synovial membrane in rheumatoid arthritis and other joint diseases. Ann Rheum Dis 1968; 27:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/13\">",
"      Lunec J, Blake DR, McCleary SJ, et al. Self-perpetuating mechanisms of immunoglobulin G aggregation in rheumatoid inflammation. J Clin Invest 1985; 76:2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/14\">",
"      Axford JS, Hay FC. Oligosaccharides, just the icing on the protein or are they of functional relevance? Br J Rheumatol 1991; 30:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/15\">",
"      Hearn PR, Russell RG, Elliott JC. Formation product of calcium pyrophosphate crystals in vitro and the effect of iron salts. Clin Sci Mol Med 1978; 54:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/16\">",
"      Hearn PR, Russell RG. Formation of calcium pyrophosphate crystals in vitro: implications for calcium pyrophosphate crystal deposition disease (pseudogout). Ann Rheum Dis 1980; 39:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/17\">",
"      McCarty DJ, Palmer DW, Garancis JC. Clearance of calcium pyrophosphate dihydrate crystals in vivo. III. Effects of synovial hemosiderosis. Arthritis Rheum 1981; 24:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/18\">",
"      COLLINS DH. Haemosiderosis and haemochromatosis of synovial tissues. J Bone Joint Surg Br 1951; 33-B:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/19\">",
"      Wyllie JC. The stromal cell reaction of pigmented villonodular synovitis: an electron microscopic study. Arthritis Rheum 1969; 12:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/20\">",
"      Key JA. Hemophilic Arthritis: Bleeder's Joints. Ann Surg 1932; 95:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/21\">",
"      Roy S, Ghadially FN. Pathology of experimental haemarthrosis. Ann Rheum Dis 1966; 25:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/22\">",
"      Axford JS, Bomford A, Revell P, et al. Hip arthropathy in genetic hemochromatosis. Radiographic and histologic features. Arthritis Rheum 1991; 34:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/23\">",
"      Martel W, Champion CK, Thompson GR, Carter TL. A roentgenologically distinctive arthropathy in some patients with the pseudogout syndrome. Am J Roentgenol Radium Ther Nucl Med 1970; 109:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/24\">",
"      Berry EM, Miller JP. Hereditary spherocytosis, haemochromatosis, diabetes mellitus and chondrocalcinosis. Proc R Soc Med 1973; 66:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/25\">",
"      Resnick D, Utsinger PD. The wrist arthropathy of \"pseudogout\" occurring with and without chondrocalcinosis. Radiology 1974; 113:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/26\">",
"      SCHUMACHER HR Jr. HEMOCHROMATOSIS AND ARTHRITIS. Arthritis Rheum 1964; 7:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/27\">",
"      de S&egrave;ze S, Solnica J, Mitrovic D, et al. Joint and bone disorders and hypoparathyroidism in hemochromatosis. Semin Arthritis Rheum 1972; 2:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/28\">",
"      Hamilton EB. Diseases associated with CPPD deposition disease. Arthritis Rheum 1976; 19 Suppl 3:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/29\">",
"      Pawlotsky Y, Le Dantec P, Moirand R, et al. Elevated parathyroid hormone 44-68 and osteoarticular changes in patients with genetic hemochromatosis. Arthritis Rheum 1999; 42:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/30\">",
"      von Kempis J. Arthropathy in hereditary hemochromatosis. Curr Opin Rheumatol 2001; 13:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/31\">",
"      de Sousa M. Immune cell functions in iron overload. Clin Exp Immunol 1989; 75:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/32\">",
"      de Martino M, Rossi ME, Resti M, et al. Changes in superoxide anion production in neutrophils from multitransfused beta-thalassemia patients: correlation with ferritin levels and liver damage. Acta Haematol 1984; 71:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/33\">",
"      Kapadia A, de Sousa M, Markenson AL, et al. Lymphoid cell sets and serum immunoglobulins in patients with thalassaemia intermedia: relationship to serum iron and splenectomy. Br J Haematol 1980; 45:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/34\">",
"      Dwyer J, Wood C, McNamara J, et al. Abnormalities in the immune system of children with beta-thalassaemia major. Clin Exp Immunol 1987; 68:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/35\">",
"      Porto G, Reim&atilde;o R, Gon&ccedil;alves C, et al. Haemochromatosis as a window into the study of the immunological system: a novel correlation between CD8+ lymphocytes and iron overload. Eur J Haematol 1994; 52:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/36\">",
"      Arosa FA, da Silva AJ, Godinho IM, et al. Decreased CD8-p56lck activity in peripheral blood T-lymphocytes from patients with hereditary haemochromatosis. Scand J Immunol 1994; 39:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/37\">",
"      Arosa FA, Oliveira L, Porto G, et al. Anomalies of the CD8+ T cell pool in haemochromatosis: HLA-A3-linked expansions of CD8+CD28- T cells. Clin Exp Immunol 1997; 107:548.",
"     </a>",
"    </li>",
"    <li>",
"     Cabeda JM, Porto G, da Silval BM, et al. Anomalies of the expression of T-cell receptor variable genes in haemochromatosis: an MHC-class I linked genetic disease of iron overload. Abstract, European Iron Club 1994, Gargano del Garda, Italy, September 24-27,1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/39\">",
"      Heiland GR, Aigner E, Dallos T, et al. Synovial immunopathology in haemochromatosis arthropathy. Ann Rheum Dis 2010; 69:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/40\">",
"      Walker RJ, Dymock IW, Ansell ID, et al. Synovial biopsy in haemochromatosis arthropathy. Histological findings and iron deposition in relation to total body iron overload. Ann Rheum Dis 1972; 31:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/41\">",
"      Bywaters EG, Hamilton EB, Williams R. The spine in idiopathic haemochromatosis. Ann Rheum Dis 1971; 30:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/42\">",
"      Sinigaglia L, Fargion S, Fracanzani AL, et al. Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. J Rheumatol 1997; 24:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/43\">",
"      Mathews JL, Williams HJ. Arthritis in hereditary hemochromatosis. Arthritis Rheum 1987; 30:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/44\">",
"      Carroll GJ, Breidahl WH, Bulsara MK, Olynyk JK. Hereditary hemochromatosis is characterized by a clinically definable arthropathy that correlates with iron load. Arthritis Rheum 2011; 63:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/45\">",
"      Charlton RW, Abrahams C, Bothwell TH. Idiopathic hemochromatosis in young subjects. Clinical, pathological, and chemical findings in four patients. Arch Pathol 1967; 83:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/46\">",
"      Cazzola M, Ascari E, Barosi G, et al. Juvenile idiopathic haemochromatosis: a life-threatening disorder presenting as hypogonadotropic hypogonadism. Hum Genet 1983; 65:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/47\">",
"      Idiopathic hemochromatosis in the young (editorial). Lancet 1984; 11:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/48\">",
"      Gordon DA, Little HA. The arthropathy of hemochromatosis without hemochromatosis. Arthritis Rheum 1973; 16:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/49\">",
"      M'Seffar A, Fornasier VL, Fox IH. Arthropathy as the major clinical indicator of occult iron storage disease. JAMA 1977; 238:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/50\">",
"      Hamilton E, Williams R, Barlow KA, Smith PM. The arthropathy of idiopathic haemochromatosis. Q J Med 1968; 37:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/51\">",
"      Adams PC, Speechley M. The effect of arthritis on the quality of life in hereditary hemochromatosis. J Rheumatol 1996; 23:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/52\">",
"      de Jonge-Bok JM, Macfarlane JD. The articular diversity of early haemochromatosis. J Bone Joint Surg Br 1987; 69:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/53\">",
"      Sahinbegovic E, Dallos T, Aigner E, et al. Musculoskeletal disease burden of hereditary hemochromatosis. Arthritis Rheum 2010; 62:3792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/54\">",
"      Hamilton EB, Bomford AB, Laws JW, Williams R. The natural history of arthritis in idiopathic haemochromatosis: progression of the clinical and radiological features over ten years. Q J Med 1981; 50:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/55\">",
"      Budiman-Mak E, Weitzner R, Lertratanakul Y. Arthropathy of hemochromatosis. Arthritis Rheum 1977; 20:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/56\">",
"      Schumacher HR Jr. Arthropathy in hemochromatosis. Hosp Pract (Minneap) 1998; 33:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/57\">",
"      Faraawi R, Harth M, Kertesz A, Bell D. Arthritis in hemochromatosis. J Rheumatol 1993; 20:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/58\">",
"      Richette P, Ottaviani S, Vicaut E, Bardin T. Musculoskeletal complications of hereditary hemochromatosis: a case-control study. J Rheumatol 2010; 37:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/59\">",
"      Sahinbegovic E, Dallos T, Aigner E, et al. Hereditary hemochromatosis as a risk factor for joint replacement surgery. Am J Med 2010; 123:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/60\">",
"      Cauza E, Hanusch-Enserer U, Etemad M, et al. HFE genotyping demonstrates a significant incidence of hemochromatosis in undifferentiated arthritis. Clin Exp Rheumatol 2005; 23:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/61\">",
"      Adamson TC 3rd, Resnik CS, Guerra J Jr, et al. Hand and wrist arthropathies of hemochromatosis and calcium pyrophosphate deposition disease: distinct radiographic features. Radiology 1983; 147:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/62\">",
"      Dallos T, Sahinbegovic E, Aigner E, et al. Validation of a radiographic scoring system for haemochromatosis arthropathy. Ann Rheum Dis 2010; 69:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/63\">",
"      Scotet V, Le Gac G, M&eacute;rour MC, et al. Impact of HFE genetic testing on clinical presentation of hereditary hemochromatosis: new epidemiological data. BMC Med Genet 2005; 6:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/64\">",
"      Cadet E, Capron D, Gallet M, et al. Reverse cascade screening of newborns for hereditary haemochromatosis: a model for other late onset diseases? J Med Genet 2005; 42:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/65\">",
"      Aigner E, Schmid I, Osterreicher CH, et al. Contribution of anti-cyclic citrullinated peptide antibody and rheumatoid factor to the diagnosis of arthropathy in haemochromatosis. Ann Rheum Dis 2007; 66:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/66\">",
"      Carroll GJ. HFE gene mutations are associated with osteoarthritis in the index or middle finger metacarpophalangeal joints. J Rheumatol 2006; 33:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/67\">",
"      Carroll GJ. Primary osteoarthritis in the ankle joint is associated with finger metacarpophalangeal osteoarthritis and the H63D mutation in the HFE gene: evidence for a hemochromatosis-like polyarticular osteoarthritis phenotype. J Clin Rheumatol 2006; 12:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/68\">",
"      Smith LH Jr. Overview of hemochromatosis. West J Med 1990; 153:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/69\">",
"      Nielsen P, Fischer R, Buggisch P, Janka-Schaub G. Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases. Br J Haematol 2003; 123:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/70\">",
"      Murray KF, Lam D, Kowdley KV. Current and future therapy in haemochromatosis and Wilson's disease. Expert Opin Pharmacother 2003; 4:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/71\">",
"      Announ N, Guerne PA. Treating difficult crystal pyrophosphate dihydrate deposition disease. Curr Rheumatol Rep 2008; 10:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/72\">",
"      Rivera S, Nemeth E, Gabayan V, et al. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 2005; 106:2196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/73\">",
"      Ezquer F, N&uacute;&ntilde;ez MT, Israel Y. Antisense gene delivered by an adenoassociated viral vector inhibits iron uptake in human intestinal cells: potential application in hemochromatosis. Biochem Pharmacol 2005; 69:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/74\">",
"      Diamond T, Stiel D, Posen S. Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med 1989; 110:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/75\">",
"      Delbarre F. Haemosiderosis and haemochromatosis of synovial tissues. J Bone Joint Surg 1960; 33:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/76\">",
"      Wardle EN, Patton JT. Bone and joint changes in haemochromatosis. Ann Rheum Dis 1969; 28:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/77\">",
"      Guggenbuhl P, Deugnier Y, Boisdet JF, et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 2005; 16:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/78\">",
"      Lunn JV, Gallagher PM, Hegarty S, et al. The role of hereditary hemochromatosis in aseptic loosening following primary total hip arthroplasty. J Orthop Res 2005; 23:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2265/abstract/79\">",
"      Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352:1769.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5618 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_13_2265=[""].join("\n");
var outline_f2_13_2265=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5295293\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS OF ARTHRITIS IN HEMOCHROMATOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Iron deposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cartilage defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Immunologic defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RADIOGRAPHIC MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chondrocalcinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CPPD disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OSTEOPOROSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ASEPTIC PROSTHETIC LOOSENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5295293\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5618\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5618|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/20/3406\" title=\"diagnostic image 1\">",
"      Hip arthritis in HH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/0/26639\" title=\"diagnostic image 2A\">",
"      Hand arthritis in HH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/1/29726\" title=\"diagnostic image 2B\">",
"      Tibiotalar arthritis in HH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/52/8015\" title=\"diagnostic image 3\">",
"      Chondrocalcinosis in HH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5618|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/63/26623\" title=\"picture 1\">",
"      Cartilage bone separation in HH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=related_link\">",
"      Diagnosis and classification of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=related_link\">",
"      Genetics of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6375?source=related_link\">",
"      Pathogenesis and etiology of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12535?source=related_link\">",
"      Screening for hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=related_link\">",
"      Treatment of hereditary hemochromatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_13_2266="Genetics of hereditary hemochromatosis";
var content_f2_13_2266=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetics of hereditary hemochromatosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/13/2266/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/13/2266/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/13/2266/contributors\">",
"     Bruce R Bacon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/13/2266/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/13/2266/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/13/2266/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/13/2266/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/13/2266/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/13/2266/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary hemochromatosis (HH), also called genetic hemochromatosis, is a genetically determined disorder in which mutations of certain genes involved in iron metabolism can cause increased intestinal iron absorption. The clinical manifestations of this disorder (and of other forms of iron overload) are related to iron deposition in tissues, such as the liver, pancreas, and heart (",
"    <a class=\"graphic graphic_table graphicRef75551 \" href=\"UTD.htm?41/32/42507\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"     \"Clinical manifestations of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The genetics of HH and our expanding understanding of the function of both the normal and mutant proteins involved in iron metabolism will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The use of genetic screening to establish the diagnosis of HH is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=see_link\">",
"     \"Treatment of hereditary hemochromatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12535?source=see_link\">",
"     \"Screening for hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE HFE GENE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since 1976, it has been known that the gene for HH is closely linked to the HLA-A3 locus, placing the gene on the short arm of chromosome 6 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/4\">",
"     4",
"    </a>",
"    ]. Previously, HLA typing had been useful in family studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/5\">",
"     5",
"    </a>",
"    ]. However, with the current clinical availability of HFE mutation analysis, such studies are no longer relevant.",
"   </p>",
"   <p>",
"    In 1996, a candidate gene for HH was identified and described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/6\">",
"     6",
"    </a>",
"    ]. Using a positional cloning technique, a novel MHC class 1-type gene, originally called HLA-H and now termed HFE, was found containing two missense mutations. One of these mutations results in a cysteine-to-tyrosine substitution at amino acid 282. Of 178 patients from 32 different medical centers around the United States, this mutation (C282Y) was found to be homozygous in 83 percent of patients with HH.",
"   </p>",
"   <p>",
"    Since this original description, confirmation has come from studies performed in a variety of other countries including France, Australia, Italy, and Germany [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. Homozygosity for the C282Y mutation has been found in 69 to 100 percent of patients with HH (",
"    <a class=\"graphic graphic_table graphicRef56137 \" href=\"UTD.htm?30/44/31436\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Data from the Third National Health and Nutrition Examination Survey (NHANES III) were used to obtain an estimate of the prevalence of the C282Y mutation in the United States population by race, ethnicity, sex, and age [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/12\">",
"     12",
"    </a>",
"    ]. The prevalence of homozygosity for C282Y for the following US populations was highest in the non-Hispanic white population (0.30 percent) and lowest in the Mexican-American population (0.03 percent).",
"   </p>",
"   <p>",
"    In a separate study of 99,711 participants recruited from primary care practices in North America, the following (self-reported) racial prevalences for C282Y homozygosity were found [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      White &mdash; 0.44 percent",
"     </li>",
"     <li>",
"      Native American &mdash; 0.11 percent",
"     </li>",
"     <li>",
"      Hispanic &mdash; 0.027 percent",
"     </li>",
"     <li>",
"      Black &mdash; 0.014 percent",
"     </li>",
"     <li>",
"      Pacific Islander &mdash; 0.012 percent",
"     </li>",
"     <li>",
"      Asian &mdash; 0.00004 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Defects in HFE other than homozygosity for C282Y",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defects other than homozygosity for C282Y can be found in patients with phenotypic HH. As an example, in a report of 90 asymptomatic patients with iron overload identified solely on the basis of screening for an elevated transferrin saturation, 57 percent were homozygous for the C282Y mutation, while 37 percent were either homozygous for the H63D mutation, heterozygous for the C282Y or H63D mutation, or compound heterozygotes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 4 to 7 percent of patients with HH are compound heterozygotes, ie, one allele with the C282Y mutation and one allele with an H63D mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/6,7,9,11,15-17\">",
"       6,7,9,11,15-17",
"      </a>",
"      ]. In at least one pedigree, diagnosed as having both juvenile hemochromatosis as well as adult-onset HH, genetic analysis indicated the presence of compound heterozygosity",
"      <span class=\"nowrap\">",
"       (C282Y/H63D)",
"      </span>",
"      along with homozygosity for a mutation in serum transferrin receptor 2 [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Approximately 1 percent of patients are homozygotes for H63D [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/15\">",
"       15",
"      </a>",
"      ]. It is uncertain, however, if the H63D mutation predisposes to iron overload, or is a genetic variant that increases the risk of developing a mild form of hemochromatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/16,19\">",
"       16,19",
"      </a>",
"      ]. A population-based study from Australia suggested that the presence of the H63D mutation was associated with an increase in the serum transferrin saturation but did not result in significant iron overload [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Approximately 3 to 10 percent of patients are heterozygotes for either C282Y or H63D (",
"      <a class=\"graphic graphic_table graphicRef56137 \" href=\"UTD.htm?30/44/31436\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/17\">",
"       17",
"      </a>",
"      ]. A possible explanation for the HH phenotype in these patients is the presence of additional mutations, either within the HFE gene or elsewhere [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/21\">",
"       21",
"      </a>",
"      ]. In one report, for example, iron overload was observed in two siblings who were compound heterozygotes for the C282Y mutation and a novel splice mutation within the HFE gene [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/22\">",
"       22",
"      </a>",
"      ]. In a second report, 16 and 7 percent of heterozygotes for the C282Y and H63D mutations, respectively, were carriers of an allele (S65C) leading to a serine-to-cysteine substitution localized to exon 2 in the vicinity of H63D [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Other gene defects leading to iron overload or high ferritin'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In four series, roughly 5 to 7 percent of patients with the HH phenotype appeared to have neither the C282Y mutation nor the H63D mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/6,9,16,17,23\">",
"       6,9,16,17,23",
"      </a>",
"      ]. A report from Italy, for example, described five unrelated patients with iron overload who were heterozygous for the C282Y mutation but also had novel mutations within the HFE gene (a G-&gt;T transition at codon 168 or a G-&gt;A transition at codon 169) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/24\">",
"       24",
"      </a>",
"      ]. The clinical significance of these less common HFE mutations is not clear at this time. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Other gene defects leading to iron overload or high ferritin'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link\">",
"       \"Iron overload syndromes other than hereditary hemochromatosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     C282Y/H63D compound heterozygotes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In various published series,",
"    <span class=\"nowrap\">",
"     C282Y/H63D",
"    </span>",
"    compound heterozygosity has been reported to account for 2 to 5 percent of cases of phenotypic HH, and a penetrance estimated at less than 1.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/9,25,26\">",
"     9,25,26",
"    </a>",
"    ]. Such patients tend to have a lesser degree of iron overload compared with C282Y homozygotes. One study suggested that compound heterozygotes did not develop progressive clinical disease or hepatic fibrosis unless a comorbid feature (eg, excess alcohol consumption, steatosis, diabetes) was also present [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Homozygous deletion of HFE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homozygous deletion of the HFE-containing region of chromosome 6p has been described in at least two cases of phenotypic HH [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     HH genotype and clinical disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is controversy concerning the percent of patients homozygous for the C282Y mutation who have, or will develop, clinically apparent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. While the definitions of \"clinically apparent disease\" differ among the studies discussed below, C282Y homozygotes appear to have a 72 to 99 percent likelihood of being free of the signs and symptoms of hereditary hemochromatosis at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population based study of 3011 white adults of northern European ancestry, homozygosity for C282Y was detected in 16 (0.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/25\">",
"       25",
"      </a>",
"      ]. All 16 had elevated transferrin saturation and all who underwent liver biopsy had hepatic iron concentrations above the upper limit of normal; however, only eight had clinical features of HH, including four with hepatic fibrosis.",
"     </li>",
"     <li>",
"      A larger screening study of over 41,000 adults attending a Kaiser Permanente health appraisal clinic in San Diego identified 152 individuals with the",
"      <span class=\"nowrap\">",
"       C282Y/C282Y",
"      </span>",
"      genotype (0.4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/31\">",
"       31",
"      </a>",
"      ]. Only 1 of the 152 homozygotes fit criteria usually applied to the clinical diagnosis of HH, suggesting a penetrance of less than 1 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12535?source=see_link&amp;anchor=H8#H8\">",
"       \"Screening for hereditary hemochromatosis\", section on 'Genetic testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The issue of disease penetrance was also studied in a prospective cohort study of 31,192 Australian subjects of northern European ancestry, in whom the incidence of C282Y homozygosity was 0.68 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/32\">",
"       32",
"      </a>",
"      ]. During 12 years of follow-up, 28 percent of male homozygotes and only 1.2 percent of female homozygotes satisfied criteria for documented iron overload plus evidence of iron-overload-related disease (ie, one or more of the following: cirrhosis, liver fibrosis, hepatocellular carcinoma, elevated aminotransferase levels, physician-diagnosed symptomatic hemochromatosis, arthropathy of the second and third metacarpophalangeal joints). Male C282Y homozygotes with a serum ferritin &ge;1000",
"      <span class=\"nowrap\">",
"       microg/L",
"      </span>",
"      were more likely to report fatigue, use of arthritis medicine, and a history of liver disease than were men who had the wild-type HFE gene.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Genetic and environmental modifiers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other genetic and environmental factors may be involved in modifying the clinical disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, the C282Y mutation occurred in 44 percent (versus 11 percent of controls) of 41 British patients with the sporadic form of porphyria cutanea tarda (PCT) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/38\">",
"       38",
"      </a>",
"      ]. Seven were homozygotes without clinical evidence of HH even though they were at an age (48 to 79) when symptoms should reasonably have occurred [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/38\">",
"       38",
"      </a>",
"      ]. Thus, for unknown reasons, PCT may be the only manifestation of homozygous HH in selected patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H5#H5\">",
"       \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Porphyria cutanea tarda'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another study compared the effect of the presence of beta thalassemia trait on the degree of iron overloading in patients homozygous for the C282Y mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/39\">",
"       39",
"      </a>",
"      ]. Among male patients with beta thalassemia trait, C282Y homozygotes were younger and had higher serum ferritin levels and hepatic iron indices than those negative for the trait. In addition, they had a higher prevalence of heart failure, clinically manifested pituitary hypogonadism, and hepatic damage.",
"     </li>",
"     <li>",
"      A single nucleotide polymorphism in the CYBRD1 gene appears to account for 11 percent of the variance in serum ferritin levels of C282Y homozygotes [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Consumption of more than 60 g of alcohol per day (the amount contained in approximately four glasses of wine or beer) was associated with a ninefold increase in the likelihood of developing cirrhosis in a cohort of 224 C282Y homozygous patients with documented iron overload [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/41\">",
"       41",
"      </a>",
"      ]. The risk was increased with alcohol consumption as little as 40 g per day. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=see_link&amp;anchor=H16#H16\">",
"       \"Treatment of hereditary hemochromatosis\", section on 'Ethanol'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Potential role of hepcidin or hemojuvelin mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overexpression of the iron regulatory protein hepcidin, produced by the HAMP gene, inhibits the iron accumulation normally observed in HFE-deficient mice [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], while loss of hepcidin expression is associated with iron overload in both animals and humans. Hemojuvelin, the protein product of the HJV gene that is mutated in patients with juvenile hemochromatosis is thought to be involved in modulating hepcidin expression. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Juvenile hemochromatosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H16#H16\">",
"     \"Regulation of iron balance\", section on 'Hepcidin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations suggest that some of the genetic heterogeneity seen in patients with \"classical\" iron overload, as well as the low incidence of clinical disease in patients homozygous or heterozygous for the C282Y HFE mutation might be due to the need for a concomitant mutation in a second gene (eg, the HAMP (hepcidin), HJV (hemojuvelin), or transferrin receptor 2 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/18\">",
"     18",
"    </a>",
"    ]) for full disease expression. Consistent with this hypothesis is the observation that creation of a deletional HAMP mutation in mice homozygous for the HFE mutation resulted in a greater iron accumulation than seen in those with only the HFE mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of observations suggest that there may be a similar interaction in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 392 patients homozygous for the C282Y HFE mutation and mild to severe iron overload, the five patients with an additional HAMP gene mutation were among those with the highest iron indices [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/46\">",
"       46",
"      </a>",
"      ]. This study also uncovered subjects heterozygous for both an HFE and a HAMP gene mutation with increased iron indices.",
"     </li>",
"     <li>",
"      In a report of 310 patients homozygous for the C282Y HFE mutation, nine were found with an additional HJV missense mutation in the heterozygous state [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/47\">",
"       47",
"      </a>",
"      ]. Iron indices in eight of the nine patients appeared to be more severe than those in C282Y homozygotes of identical sex and similar age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     THE HFE PROTEIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HFE protein is a single polypeptide with three extracellular domains (",
"    <a class=\"graphic graphic_figure graphicRef57597 \" href=\"UTD.htm?27/59/28594\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/48\">",
"     48",
"    </a>",
"    ]. It also contains a membrane spanning region and a short cytoplasmic tail. As discussed in this section, the C282Y mutation appears to inactivate the HFE protein through its inability to bind beta 2-microglobulin, leading to impaired cellular trafficking, reduced incorporation into the cell membrane, and reduced association with transferrin receptor 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunohistochemical studies have shown a unique distribution of the HFE protein in the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/50\">",
"     50",
"    </a>",
"    ]. In particular, staining in the small intestine was mainly intracellular and perinuclear, limited to cells in deep crypts in proximity to the site of iron absorption. Studies with an HFE-specific monoclonal antibody confirmed its presence in scattered crypt cells in association with the transferrin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/51\">",
"     51",
"    </a>",
"    ]. HFE was also identified in Kupffer cells and sinusoidal lining cells but not hepatic parenchymal cells.",
"   </p>",
"   <p>",
"    A role for MHC class I proteins in iron absorption was also suggested by observations in beta-2-microglobulin knockout mice [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/52\">",
"     52",
"    </a>",
"    ]. Beta-2-microglobulin is the nonpolymorphic light chain of MHC class I proteins; it is a separate protein and is expected to interact with the HFE protein in a noncovalent manner. Deficiency of beta-2-microglobulin is associated with iron overload and findings similar to those in HH in humans: elevations in the plasma iron concentration and transferrin saturation and an increase in hepatic iron content [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/53\">",
"     53",
"    </a>",
"    ]. An unexplained observation in both HH and the knockout mouse is that transferrin saturation initially remains elevated as iron stores are being depleted.",
"   </p>",
"   <p>",
"    Direct evidence that mutations in HFE are responsible for HH has come from studies of HFE knockout mice [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/54\">",
"     54",
"    </a>",
"    ]. Compared with their normal littermates, these mice develop, after 10 weeks on a standard diet, an elevation in transferrin saturation (96 versus 77 percent) and an eightfold increase in hepatic iron concentration. Iron is preferentially deposited in hepatocytes rather than reticuloendothelial cells, and splenic iron overload does not appear over this time period.",
"   </p>",
"   <p>",
"    The cellular interaction between beta-2-microglobulin and wild-type HFE and two mutations has been examined: C282Y, which, as noted above, is responsible for most cases of HH; and H63D, which has an uncertain relationship to iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wild-type HFE and H63D HFE bound beta-2-microglobulin; this interaction was not seen with C282Y HFE.",
"     </li>",
"     <li>",
"      Wild type and H63D HFE were expressed on the cell surface whereas C282Y HFE was localized intracellularly; the C282Y mutant appears to be retained in the endoplasmic reticulum and Golgi compartment [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another report provides a possible link between HFE, beta-2- microglobulin, and iron metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/57\">",
"     57",
"    </a>",
"    ]. In the human placenta, the HFE protein is expressed at the site at which transferrin-bound iron is transported to the fetus via receptor-mediated endocytosis. At this site, the",
"    <span class=\"nowrap\">",
"     HFE/beta-2-microglobulin",
"    </span>",
"    complex binds to the transferrin receptor, an effect that is not seen with the mutant C282Y HFE protein [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/49,58\">",
"     49,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Role in iron absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;How these changes lead to increased iron absorption is incompletely understood, since HFE protein and the transferrin receptor are expressed in crypt cells but iron transport seems to occur in villus cells [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/59\">",
"     59",
"    </a>",
"    ]. Studies in human duodenal cells have shown that crypt cell fractions exhibit higher transferrin-bound iron uptake than villus cells, while villus cells showed two to three times higher uptake of ionic iron than crypt cells [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Crypt cell model",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings noted above have led to the postulate that the role of the HFE protein is to modulate the uptake of transferrin-bound iron into crypt cells, allowing the complex to act as a sensor of body iron stores [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link\">",
"     \"Regulation of iron balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this proposed model of the regulation of iron absorption, the following steps would occur (",
"    <a class=\"graphic graphic_figure graphicRef52130 \" href=\"UTD.htm?4/23/4465\">",
"     figure 2",
"    </a>",
"    ). Increased body iron stores and the accompanying rise in transferrin-bound iron lead to enhanced uptake of iron into crypt cells. As a result of the ensuing increase in intracellular iron, the differentiating enterocytes migrating up to the villus tip downregulate the production of the iron transporter DMT1, reducing the absorption of dietary iron. This process is reversed in iron deficiency as iron transporters in the developing villus cells and iron absorption are increased.",
"   </p>",
"   <p>",
"    In hereditary hemochromatosis, mutations in HFE may impair TfR-mediated uptake of transferrin-bound iron into crypt cells, providing a false signal that iron stores are low.",
"   </p>",
"   <p>",
"    In support of this postulated model are studies in normal and HFE knockout mice [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/61\">",
"     61",
"    </a>",
"    ]. In wild-type",
"    <span class=\"nowrap\">",
"     (+/+)",
"    </span>",
"    mice, iron deficiency leads to greatly increased levels of a duodenal divalent metal transporter containing an iron-responsive element [DMT1 (IRE)]. In HFE knockout",
"    <span class=\"nowrap\">",
"     (-/-)",
"    </span>",
"    mice, levels of duodenal DMT1 (IRE) were increased an average of 7.7-fold over their normal littermate controls, thereby maintaining the abnormally increased iron absorption in the presence of iron overload and an elevated transferrin saturation.",
"   </p>",
"   <p>",
"    These observations in the mouse model also appear to apply to humans with HH. In one study, DMT1 cDNA and mRNA levels in duodenal biopsies were markedly increased in patients with HH",
"    <span class=\"nowrap\">",
"     (C282Y/C282Y)",
"    </span>",
"    compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/65\">",
"     65",
"    </a>",
"    ]. Furthermore, patients with HH lacked the expected inverse correlation between the levels of duodenal DMT1 and serum ferritin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Liver model",
"    </span>",
"    &nbsp;&mdash;&nbsp;A competing model suggests that the HFE protein functions to regulate iron absorption through a direct or indirect (eg, through hepatic macrophages) interaction with hepatocytes, which express genes (eg, hepcidin, transferrin receptor 2, hemojuvelin) that lead to hemochromatosis if mutated or otherwise inhibited [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Potential role of hepcidin or hemojuvelin mutations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'Other gene defects leading to iron overload or high ferritin'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H16#H16\">",
"     \"Regulation of iron balance\", section on 'Hepcidin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This model is supported by two major findings in animals and humans:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In both patients and mice, HFE deficiency correlates with inappropriately low basal expression of hepcidin [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/67-71\">",
"       67-71",
"      </a>",
"      ], potentially leading to increased intestinal iron absorption through a lack of the inhibitory effect of hepcidin on the iron export protein ferroportin (",
"      <a class=\"graphic graphic_figure graphicRef66578 \" href=\"UTD.htm?38/11/39088\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Experiments in mice in which HFE expression was exclusively abolished in the intestine have shown that intestinal HFE was dispensable for the physiologic control of systemic iron homeostasis under steady state conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OTHER GENE DEFECTS LEADING TO IRON OVERLOAD OR HIGH FERRITIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the population studied, from 5 to more than 75 percent of patients with phenotypic HH are not homozygous for the C282Y HFE mutation, suggesting that their iron overload is due to a defect in one (or more) of the other proteins involved in iron metabolism (",
"    <a class=\"graphic graphic_table graphicRef56137 \" href=\"UTD.htm?30/44/31436\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link\">",
"     \"Regulation of iron balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At the present time, mutations in a number of other proteins have been associated with various forms of iron overload or hyperferritinemia, although most have been reported in only a small number of families (",
"    <a class=\"graphic graphic_table graphicRef56329 \" href=\"UTD.htm?16/60/17356\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/74-77\">",
"     74-77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Juvenile hemochromatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An uncommon but more severe form of HH occurs in childhood and is termed juvenile or type II hemochromatosis (JH). The affected gene in JH has been mapped to the long arm of chromosome 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/78,79\">",
"     78,79",
"    </a>",
"    ] and was initially called HFE2 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/80\">",
"     80",
"    </a>",
"    ], but now more properly renamed HJV [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/81\">",
"     81",
"    </a>",
"    ]. Its protein product, hemojuvelin, is expressed in liver, heart, and skeletal muscle, and is thought to be involved in modulating hepcidin expression [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/80,82,83\">",
"     80,82,83",
"    </a>",
"    ], perhaps via selective inhibition of bone morphogenetic protein signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study of 12 unrelated Greek, Canadian, and French families, individuals with JH were either homozygous or compound heterozygotes for mutations in HFE2, and uniformly showed reduced urinary hepcidin levels.",
"   </p>",
"   <p>",
"    Juvenile hemochromatosis is earlier in onset, develops at a greater rate than typical HH, and appears genetically distinct [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. The disease has been most commonly reported in Italy, where at least 17 different HJV mutations have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/79\">",
"     79",
"    </a>",
"    ]. Affected individuals are more likely to present with cardiomyopathy, reduced glucose tolerance, and hypogonadism, rather than severe liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three separate families with a clinical diagnosis of JH have been found with loss-of-function mutations involving the gene encoding hepcidin (HAMP), found on chromosome 19 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. Since levels of hepcidin correlate inversely with rates of intestinal iron absorption and release of iron from macrophages, the low levels of hepcidin seen in JH are consistent with the markedly increased intestinal iron absorption as well as the presence of iron-depleted macrophages, both of which are characteristic of this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H16#H16\">",
"     \"Regulation of iron balance\", section on 'Hepcidin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Transferrin receptor 2 mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron overload due to mutations of transferrin receptor 2 (TFR2) is uncommon, having been described in only eight pedigrees to date, due to homozygosity for inactivating mutations of TFR2 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/75,91-94\">",
"     75,91-94",
"    </a>",
"    ]. Clinical descriptions of patients with this autosomal recessive disorder are sparse. However, the clinical phenotype appears to be similar to [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/75\">",
"     75",
"    </a>",
"    ], or slightly worse than [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/94\">",
"     94",
"    </a>",
"    ], that of classical hereditary hemochromatosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H5#H5\">",
"     \"Regulation of iron balance\", section on 'Transferrin receptor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ferroportin mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mutation in a gene encoding for ferroportin (SLC40A1, previously called SLC11A3) was associated with an autosomal dominant form of hemochromatosis in unrelated European and Australian families [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/95-102\">",
"     95-102",
"    </a>",
"    ]. The SLC40A1 gene encodes for a basolateral membrane protein that has a role in the movement of iron across the enterocytes and macrophages into the circulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H13#H13\">",
"     \"Regulation of iron balance\", section on 'Ferroportin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, ferroportin mutations have had heterogeneous clinical presentations, suggesting the presence of additional cofactors affecting disease penetrance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/103\">",
"     103",
"    </a>",
"    ]. While some families have had a disorder similar to, or more severe than, classical HH, other families have manifested a mild disorder with high ferritin levels, normal or low transferrin saturation, mild anemia, and mild organ disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/23,104,105\">",
"     23,104,105",
"    </a>",
"    ]. Liver biopsy has shown increased concentrations of iron, although, unlike classical hemochromatosis, the iron is considerably more prominent in Kupffer cells than in hepatocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/97-99,106\">",
"     97-99,106",
"    </a>",
"    ]. Liver disease is limited to signs of fibrosis, primarily sinusoidal [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reduced export of iron from macrophages is felt to be responsible for the low saturation of transferrin seen in these latter families, as well as the mild anemia. In young females, hypochromic microcytic anemia may develop, which is responsive to treatment with oral iron supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/75\">",
"     75",
"    </a>",
"    ]. Ferroportin-associated iron overload responds to treatment with venesection, although the reduced rate of iron export from macrophages makes these patients more prone to develop anemia following venesection than those with classical hereditary hemochromatosis, in which disorder this export function is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An explanation for why mutations in ferroportin produce such heterogeneous effects has come from an understanding of how these mutations affect the function of ferroportin and its interaction with hepcidin [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/107-112\">",
"     107-112",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Classical ferroportin disease",
"      </strong>",
"      &mdash; Some mutations produce a molecule which either does not traffic appropriately to the cell surface or which has limited ability to export iron, as in panel D of the figure (",
"      <a class=\"graphic graphic_figure graphicRef66578 \" href=\"UTD.htm?38/11/39088\">",
"       figure 3",
"      </a>",
"      ). These \"loss of function\" mutations result in excess accumulation of iron in macrophages, with resulting high serum ferritin, normal to reduced transferrin iron saturation, and a mild anemia. This has also been called macrophage-type (M-type) ferroportin disease.",
"     </li>",
"     <li>",
"      <strong>",
"       Non-classical ferroportin disease",
"      </strong>",
"      &mdash; Other mutations produce a ferroportin resistant to inhibition by the iron regulatory molecule hepcidin, retaining full iron export capability, as in panel E of the figure (",
"      <a class=\"graphic graphic_figure graphicRef66578 \" href=\"UTD.htm?38/11/39088\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/113-115\">",
"       113-115",
"      </a>",
"      ]. These \"gain of function\" mutations allow iron to be absorbed in excess of need, with patients manifesting high levels of ferritin and hepcidin, increased transferrin saturations, and typical deposition of iron in the hepatic parenchyma. This has also been called hepatic-type ferroportin disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Aceruloplasminemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upon its release from ferroportin, ferrous iron is oxidized to the ferric form, and loaded onto transferrin. This oxidation process involves ceruloplasmin, a known copper dependent multioxidase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H24#H24\">",
"     \"Regulation of iron balance\", section on 'Iron release from macrophages'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hereditary aceruloplasminemia is a rare inherited disease caused by homozygous mutation of the ceruloplasmin gene and is characterized by anemia, iron overload, diabetes, and neurodegeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/116\">",
"     116",
"    </a>",
"    ]. As with those having ferroportin mutations, such patients are anemic and do not tolerate treatment with phlebotomy. However, these patients do respond to treatment with iron chelating agents [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/116-118\">",
"     116-118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     H-ferritin mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single point mutation in the iron responsive element motif of H-ferritin mRNA has been found in four of seven members of a Japanese family affected by dominantly inherited iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/119\">",
"     119",
"    </a>",
"    ]. No additional clinical information concerning this family is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hyperferritinemia without iron overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several ferritin mutations exist which have resulted in exceedingly high ferritin levels without systemic iron overload.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14441036\">",
"    <span class=\"h3\">",
"     Hereditary hyperferritinemia-cataract syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations have been described in which otherwise asymptomatic individuals in affected families have exceedingly high serum ferritin levels (often &gt;1,000",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    without tissue iron overload, in association with bilateral congenital cataracts. This disorder, which has been termed \"hereditary hyperferritinemia-cataract syndrome\" is inherited in an autosomal dominant manner, and appears to involve a number of different mutations in the iron responsive element of L-ferritin [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/120-123\">",
"     120-123",
"    </a>",
"    ]. A direct relationship between the degree of hyperferritinemia and severity of cataract suggests that the latter is a consequence of excessive ferritin production within the lens fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14441043\">",
"    <span class=\"h3\">",
"     Benign hyperferritinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A \"benign hyperferritinemia\" without clinical manifestations or iron overload, due to a mutation in the coding region of L-ferritin has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Neuroferritinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroferritinopathy, also named dominant adult-onset basal ganglia disease, is a dominantly inherited movement disorder characterized by deposition of iron and ferritin in the brain, normal or low serum ferritin levels, and highly variable clinical features. The disease is associated with nucleotide insertions that modify the ferritin L-chain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/13/2266/abstract/126\">",
"     126",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15943?source=see_link&amp;anchor=H10#H10\">",
"     \"Bradykinetic movement disorders in children\", section on 'Neurodegeneration with brain iron accumulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40179?source=see_link\">",
"       \"Patient information: Hemochromatosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/41/2709?source=see_link\">",
"       \"Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3358599\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary hemochromatosis (HH) is a genetically determined disorder in which mutations of certain genes involved in iron metabolism can cause increased intestinal iron absorption, resulting in excess iron in tissues with resulting damage, especially in the liver, heart, and pancreas. The most common of these are listed below (",
"    <a class=\"graphic graphic_table graphicRef56329 \" href=\"UTD.htm?16/60/17356\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       HFE (type I)",
"      </strong>",
"      &mdash; Mutations in the HFE gene are responsible for the vast majority of patients with HH (",
"      <a class=\"graphic graphic_table graphicRef56137 \" href=\"UTD.htm?30/44/31436\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'The HFE gene'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'The HFE protein'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Juvenile hemochromatosis (type II)",
"      </strong>",
"      &mdash; Mutations in HJV (type IIA, protein product: hemojuvelin) and HAMP (type IIB, protein product: hepcidin) are responsible for juvenile hemochromatosis, which is earlier in onset and develops at a greater rate than classical HH. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Juvenile hemochromatosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Transferrin receptor 2 mutation (type III)",
"      </strong>",
"      &mdash; The clinical phenotype of this rare autosomal recessive disorder appears to be similar to, or slightly worse than, that of classical HH. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Transferrin receptor 2 mutation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Ferroportin mutations (type IV)",
"      </strong>",
"      &mdash; Mutations in a gene encoding for ferroportin (SLC40A1) are responsible for two different phenotypes (",
"      <a class=\"graphic graphic_figure graphicRef66578 \" href=\"UTD.htm?38/11/39088\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Ferroportin mutations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Macrophage type",
"      </strong>",
"      &mdash; These \"loss of function\" mutations result in excess accumulation of iron in macrophages, with resulting high serum ferritin, normal to reduced transferrin iron saturation, and a mild anemia.",
"     </li>",
"     <li>",
"      <strong>",
"       Hepatic type",
"      </strong>",
"      &mdash; These \"gain of function\" mutations allow iron to be absorbed in excess of need, with patients manifesting high levels of ferritin and hepcidin, increased transferrin saturations, and typical deposition of iron in the hepatic parenchyma.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/1\">",
"      Pietrangelo A. Hereditary hemochromatosis--a new look at an old disease. N Engl J Med 2004; 350:2383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/2\">",
"      Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood 2005; 106:3710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/3\">",
"      Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med 2012; 366:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/4\">",
"      Simon M, Bourel M, Fauchet R, Genetet B. Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis. Gut 1976; 17:332.",
"     </a>",
"    </li>",
"    <li>",
"     Bacon BR, Tavill AS. Hemochromatosis and the iron overload syndromes. In: Hepatology, A Textbook of Liver Disease, Zakim D, Boyer TD (Eds), WB Saunders, Philadelphia 1996. p.1439.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/6\">",
"      Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/7\">",
"      Jouanolle AM, Gandon G, J&eacute;z&eacute;quel P, et al. Haemochromatosis and HLA-H. Nat Genet 1996; 14:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/8\">",
"      Jazwinska EC, Cullen LM, Busfield F, et al. Haemochromatosis and HLA-H. Nat Genet 1996; 14:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/9\">",
"      Beutler E, Gelbart T, West C, et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 1996; 22:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/10\">",
"      Carella M, D'Ambrosio L, Totaro A, et al. Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. Am J Hum Genet 1997; 60:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/11\">",
"      Nielsen P, Carpinteiro S, Fischer R, et al. Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany. Br J Haematol 1998; 103:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/12\">",
"      Steinberg KK, Cogswell ME, Chang JC, et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001; 285:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/13\">",
"      Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/14\">",
"      Sham RL, Raubertas RF, Braggins C, et al. Asymptomatic hemochromatosis subjects: genotypic and phenotypic profiles. Blood 2000; 96:3707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/15\">",
"      Bacon BR. Diagnosis and management of hemochromatosis. Gastroenterology 1997; 113:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/16\">",
"      Mura C, Raguenes O, F&eacute;rec C. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood 1999; 93:2502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/17\">",
"      Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol 2001; 154:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/18\">",
"      Pietrangelo A, Caleffi A, Henrion J, et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology 2005; 128:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/19\">",
"      Bacon BR, Olynyk JK, Brunt EM, et al. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999; 130:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/20\">",
"      Gochee PA, Powell LW, Cullen DJ, et al. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 2002; 122:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/21\">",
"      van Dijk BA, Kemna EH, Tjalsma H, et al. Effect of the new HJV-L165X mutation on penetrance of HFE. Blood 2007; 109:5525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/22\">",
"      Wallace DF, Dooley JS, Walker AP. A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote. Gastroenterology 1999; 116:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/23\">",
"      Pietrangelo A, Montosi G, Totaro A, et al. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med 1999; 341:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/24\">",
"      Piperno A, Arosio C, Fossati L, et al. Two novel nonsense mutations of HFE gene in five unrelated italian patients with hemochromatosis. Gastroenterology 2000; 119:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/25\">",
"      Olynyk JK, Cullen DJ, Aquilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/26\">",
"      Walsh A, Dixon JL, Ramm GA, et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol 2006; 4:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/27\">",
"      Le Gac G, Gourlaouen I, Ronsin C, et al. Homozygous deletion of HFE produces a phenotype similar to the HFE p.C282Y/p.C282Y genotype. Blood 2008; 112:5238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/28\">",
"      Pelucchi S, Mariani R, Bertola F, et al. Homozygous deletion of HFE: the Sardinian hemochromatosis? Blood 2009; 113:3886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/29\">",
"      Beutler E. The HFE Cys282Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis. Blood 2003; 101:3347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/30\">",
"      Ajioka RS, Kushner JP. Clinical consequences of iron overload in hemochromatosis homozygotes. Blood 2003; 101:3351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/31\">",
"      Beutler E, Felitti VJ, Koziol JA, et al. Penetrance of 845G--&gt; A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/32\">",
"      Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/33\">",
"      Bacon BR, Britton RS. Clinical penetrance of hereditary hemochromatosis. N Engl J Med 2008; 358:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/34\">",
"      Fleming RE, Holden CC, Tomatsu S, et al. Mouse strain differences determine severity of iron accumulation in Hfe knockout model of hereditary hemochromatosis. Proc Natl Acad Sci U S A 2001; 98:2707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/35\">",
"      Beutler E. Discrepancies between genotype and phenotype in hematology: an important frontier. Blood 2001; 98:2597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/36\">",
"      Cardoso EM, Macedo MG, Rohrlich P, et al. Increased hepatic iron in mice lacking classical MHC class I molecules. Blood 2002; 100:4239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/37\">",
"      Pelucchi S, Mariani R, Calza S, et al. CYBRD1 as a modifier gene that modulates iron phenotype in HFE p.C282Y homozygous patients. Haematologica 2012; 97:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/38\">",
"      Roberts AG, Whatley SD, Morgan RR, et al. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997; 349:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/39\">",
"      Piperno A, Mariani R, Arosio C, et al. Haemochromatosis in patients with beta-thalassaemia trait. Br J Haematol 2000; 111:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/40\">",
"      Constantine CC, Anderson GJ, Vulpe CD, et al. A novel association between a SNP in CYBRD1 and serum ferritin levels in a cohort study of HFE hereditary haemochromatosis. Br J Haematol 2009; 147:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/41\">",
"      Fletcher LM, Dixon JL, Purdie DM, et al. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 2002; 122:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/42\">",
"      Nicolas G, Viatte L, Lou DQ, et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet 2003; 34:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/43\">",
"      Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/44\">",
"      Nicolas G, Andrews NC, Kahn A, Vaulont S. Hepcidin, a candidate modifier of the hemochromatosis phenotype in mice. Blood 2004; 103:2841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/45\">",
"      Merryweather-Clarke AT, Cadet E, Bomford A, et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 2003; 12:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/46\">",
"      Jacolot S, Le Gac G, Scotet V, et al. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 2004; 103:2835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/47\">",
"      Le Gac G, Scotet V, Ka C, et al. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum Mol Genet 2004; 13:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/48\">",
"      Andrews NC, Levy JE. Iron is hot: an update on the pathophysiology of hemochromatosis. Blood 1998; 92:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/49\">",
"      Feder JN, Penny DM, Irrinki A, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A 1998; 95:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/50\">",
"      Parkkila S, Waheed A, Britton RS, et al. Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals unique pattern of expression in gastrointestinal tract. Proc Natl Acad Sci U S A 1997; 94:2534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/51\">",
"      Bastin JM, Jones M, O'Callaghan CA, et al. Kupffer cell staining by an HFE-specific monoclonal antibody: implications for hereditary haemochromatosis. Br J Haematol 1998; 103:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/52\">",
"      Rothenberg BE, Voland JR. beta2 knockout mice develop parenchymal iron overload: A putative role for class I genes of the major histocompatibility complex in iron metabolism. Proc Natl Acad Sci U S A 1996; 93:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/53\">",
"      Santos M, Schilham MW, Rademakers LH, et al. Defective iron homeostasis in beta 2-microglobulin knockout mice recapitulates hereditary hemochromatosis in man. J Exp Med 1996; 184:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/54\">",
"      Zhou XY, Tomatsu S, Fleming RE, et al. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci U S A 1998; 95:2492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/55\">",
"      Feder JN, Tsuchihashi Z, Irrinki A, et al. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem 1997; 272:14025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/56\">",
"      Waheed A, Parkkila S, Zhou XY, et al. Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci U S A 1997; 94:12384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/57\">",
"      Parkkila S, Waheed A, Britton RS, et al. Association of the transferrin receptor in human placenta with HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci U S A 1997; 94:13198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/58\">",
"      Lebr&oacute;n JA, Bennett MJ, Vaughn DE, et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 1998; 93:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/59\">",
"      Parkkila S, Niemel&auml; O, Britton RS, et al. Molecular aspects of iron absorption and HFE expression. Gastroenterology 2001; 121:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/60\">",
"      Waheed A, Parkkila S, Saarnio J, et al. Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum. Proc Natl Acad Sci U S A 1999; 96:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/61\">",
"      Fleming RE, Migas MC, Zhou X, et al. Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: increased duodenal expression of the iron transporter DMT1. Proc Natl Acad Sci U S A 1999; 96:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/62\">",
"      Bacon BR, Powell LW, Adams PC, et al. Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology 1999; 116:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/63\">",
"      Waheed A, Grubb JH, Zhou XY, et al. Regulation of transferrin-mediated iron uptake by HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci U S A 2002; 99:3117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/64\">",
"      Trinder D, Olynyk JK, Sly WS, Morgan EH. Iron uptake from plasma transferrin by the duodenum is impaired in the Hfe knockout mouse. Proc Natl Acad Sci U S A 2002; 99:5622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/65\">",
"      Zoller H, Pietrangelo A, Vogel W, Weiss G. Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis. Lancet 1999; 353:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/66\">",
"      Fleming RE. Crypt cell hypothesis: technical knockout. Blood 2007; 109:4114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/67\">",
"      Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 2003; 361:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/68\">",
"      Gehrke SG, Kulaksiz H, Herrmann T, et al. Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron. Blood 2003; 102:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/69\">",
"      Nemeth E, Roetto A, Garozzo G, et al. Hepcidin is decreased in TFR2 hemochromatosis. Blood 2005; 105:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/70\">",
"      Muckenthaler M, Roy CN, Custodio AO, et al. Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis. Nat Genet 2003; 34:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/71\">",
"      van Dijk BA, Laarakkers CM, Klaver SM, et al. Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels. Br J Haematol 2008; 142:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/72\">",
"      Vujic Spasic M, Kiss J, Herrmann T, et al. Physiologic systemic iron metabolism in mice deficient for duodenal Hfe. Blood 2007; 109:4511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/73\">",
"      Lok CY, Merryweather-Clarke AT, Viprakasit V, et al. Iron overload in the Asian community. Blood 2009; 114:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/74\">",
"      Bomford A. Genetics of haemochromatosis. Lancet 2002; 360:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/75\">",
"      Pietrangelo A. Non-HFE hemochromatosis. Hepatology 2004; 39:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/76\">",
"      Zoller H, Cox TM. Hemochromatosis: genetic testing and clinical practice. Clin Gastroenterol Hepatol 2005; 3:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/77\">",
"      Camaschella C, Poggiali E. Towards explaining \"unexplained hyperferritinemia\". Haematologica 2009; 94:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/78\">",
"      Roetto A, Totaro A, Cazzola M, et al. Juvenile hemochromatosis locus maps to chromosome 1q. Am J Hum Genet 1999; 64:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/79\">",
"      Lanzara C, Roetto A, Daraio F, et al. Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood 2004; 103:4317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/80\">",
"      Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/81\">",
"      Lee PL, Beutler E, Rao SV, Barton JC. Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin. Blood 2004; 103:4669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/82\">",
"      Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood 2005; 106:2884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/83\">",
"      Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006; 38:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/84\">",
"      Babitt JL, Huang FW, Xia Y, et al. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 2007; 117:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/85\">",
"      Xia Y, Babitt JL, Sidis Y, et al. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood 2008; 111:5195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/86\">",
"      Camaschella C, Roetto A, Cicilano M, et al. Juvenile and adult hemochromatosis are distinct genetic disorders. Eur J Hum Genet 1997; 5:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/87\">",
"      Kelly AL, Rhodes DA, Roland JM, et al. Hereditary juvenile haemochromatosis: a genetically heterogeneous life-threatening iron-storage disease. QJM 1998; 91:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/88\">",
"      Camaschella C, Fargion S, Sampietro M, et al. Inherited HFE-unrelated hemochromatosis in Italian families. Hepatology 1999; 29:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/89\">",
"      Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003; 33:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/90\">",
"      Matthes T, Aguilar-Martinez P, Pizzi-Bosman L, et al. Severe hemochromatosis in a Portuguese family associated with a new mutation in the 5'-UTR of the HAMP gene. Blood 2004; 104:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/91\">",
"      Roetto A, Totaro A, Piperno A, et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 2001; 97:2555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/92\">",
"      Girelli D, Bozzini C, Roetto A, et al. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Gastroenterology 2002; 122:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/93\">",
"      Mattman A, Huntsman D, Lockitch G, et al. Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood 2002; 100:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/94\">",
"      Le Gac G, Mons F, Jacolot S, et al. Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent. Br J Haematol 2004; 125:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/95\">",
"      Njajou OT, Vaessen N, Joosse M, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001; 28:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/96\">",
"      Montosi G, Donovan A, Totaro A, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001; 108:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/97\">",
"      Wallace DF, Pedersen P, Dixon JL, et al. Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis. Blood 2002; 100:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/98\">",
"      Devalia V, Carter K, Walker AP, et al. Autosomal dominant reticuloendothelial iron overload associated with a 3-base pair deletion in the ferroportin 1 gene (SLC11A3). Blood 2002; 100:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/99\">",
"      Roetto A, Merryweather-Clarke AT, Daraio F, et al. A valine deletion of ferroportin 1: a common mutation in hemochromastosis type 4. Blood 2002; 100:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/100\">",
"      Camaschella C, Roetto A, De Gobbi M. Genetic haemochromatosis: genes and mutations associated with iron loading. Best Pract Res Clin Haematol 2002; 15:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/101\">",
"      Zohn IE, De Domenico I, Pollock A, et al. The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease. Blood 2007; 109:4174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/102\">",
"      Gall&iacute; A, Bergamaschi G, Recalde H, et al. Ferroportin gene silencing induces iron retention and enhances ferritin synthesis in human macrophages. Br J Haematol 2004; 127:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/103\">",
"      Le Lan C, Mosser A, Ropert M, et al. Sex and acquired cofactors determine phenotypes of ferroportin disease. Gastroenterology 2011; 140:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/104\">",
"      Cremonesi L, Cemonesi L, Forni GL, et al. Genetic and clinical heterogeneity of ferroportin disease. Br J Haematol 2005; 131:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/105\">",
"      Griffiths WJ, Mayr R, McFarlane I, et al. Clinical presentation and molecular pathophysiology of autosomal dominant hemochromatosis caused by a novel ferroportin mutation. Hepatology 2010; 51:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/106\">",
"      Cazzola M, Cremonesi L, Papaioannou M, et al. Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3). Br J Haematol 2002; 119:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/107\">",
"      Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/108\">",
"      Drakesmith H, Schimanski LM, Ormerod E, et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood 2005; 106:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/109\">",
"      De Domenico I, Ward DM, Nemeth E, et al. The molecular basis of ferroportin-linked hemochromatosis. Proc Natl Acad Sci U S A 2005; 102:8955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/110\">",
"      Schimanski LM, Drakesmith H, Merryweather-Clarke AT, et al. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood 2005; 105:4096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/111\">",
"      De Domenico I, Vaughn MB, Yoon D, et al. Zebrafish as a model for defining the functional impact of mammalian ferroportin mutations. Blood 2007; 110:3780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/112\">",
"      Mayr R, Janecke AR, Schranz M, et al. Ferroportin disease: a systematic meta-analysis of clinical and molecular findings. J Hepatol 2010; 53:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/113\">",
"      Fernandes A, Preza GC, Phung Y, et al. The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood 2009; 114:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/114\">",
"      Sham RL, Phatak PD, Nemeth E, Ganz T. Hereditary hemochromatosis due to resistance to hepcidin: high hepcidin concentrations in a family with C326S ferroportin mutation. Blood 2009; 114:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/115\">",
"      L&eacute;tocart E, Le Gac G, Majore S, et al. A novel missense mutation in SLC40A1 results in resistance to hepcidin and confirms the existence of two ferroportin-associated iron overload diseases. Br J Haematol 2009; 147:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/116\">",
"      Fasano A, Colosimo C, Miyajima H, et al. Aceruloplasminemia: a novel mutation in a family with marked phenotypic variability. Mov Disord 2008; 23:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/117\">",
"      Lor&eacute;al O, Turlin B, Pigeon C, et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J Hepatol 2002; 36:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/118\">",
"      Miyajima H, Takahashi Y, Kamata T, et al. Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 1997; 41:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/119\">",
"      Kato J, Fujikawa K, Kanda M, et al. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet 2001; 69:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/120\">",
"      Girelli D, Corrocher R, Bisceglia L, et al. Hereditary hyperferritinemia-cataract syndrome caused by a 29-base pair deletion in the iron responsive element of ferritin L-subunit gene. Blood 1997; 90:2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/121\">",
"      Arnold JD, Mumford AD, Lindsay JO, et al. Hyperferritinaemia in the absence of iron overload. Gut 1997; 41:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/122\">",
"      Hetet G, Devaux I, Soufir N, et al. Molecular analyses of patients with hyperferritinemia and normal serum iron values reveal both L ferritin IRE and 3 new ferroportin (slc11A3) mutations. Blood 2003; 102:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/123\">",
"      Cazzola M. Hereditary hyperferritinaemia/ cataract syndrome. Best Pract Res Clin Haematol 2002; 15:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/124\">",
"      Cazzola M, Bergamaschi G, Tonon L, et al. Hereditary hyperferritinemia-cataract syndrome: relationship between phenotypes and specific mutations in the iron-responsive element of ferritin light-chain mRNA. Blood 1997; 90:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/125\">",
"      Kannengiesser C, Jouanolle AM, Hetet G, et al. A new missense mutation in the L ferritin coding sequence associated with elevated levels of glycosylated ferritin in serum and absence of iron overload. Haematologica 2009; 94:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/13/2266/abstract/126\">",
"      Levi S, Cozzi A, Arosio P. Neuroferritinopathy: a neurodegenerative disorder associated with L-ferritin mutation. Best Pract Res Clin Haematol 2005; 18:265.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7067 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-FC54B750F8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_13_2266=[""].join("\n");
var outline_f2_13_2266=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3358599\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE HFE GENE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Defects in HFE other than homozygosity for C282Y",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - C282Y/H63D compound heterozygotes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Homozygous deletion of HFE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HH genotype and clinical disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Genetic and environmental modifiers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Potential role of hepcidin or hemojuvelin mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      THE HFE PROTEIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Role in iron absorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Crypt cell model",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Liver model",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OTHER GENE DEFECTS LEADING TO IRON OVERLOAD OR HIGH FERRITIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Juvenile hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Transferrin receptor 2 mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ferroportin mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Aceruloplasminemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      H-ferritin mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hyperferritinemia without iron overload",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14441036\">",
"      - Hereditary hyperferritinemia-cataract syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14441043\">",
"      - Benign hyperferritinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Neuroferritinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3358599\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7067\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7067|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/59/28594\" title=\"figure 1\">",
"      Model of the HFE protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/23/4465\" title=\"figure 2\">",
"      Iron absorption model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/11/39088\" title=\"figure 3\">",
"      Ferroportin hepcidin function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7067|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/32/42507\" title=\"table 1\">",
"      Iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/44/31436\" title=\"table 2\">",
"      HFE genotype in HH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/60/17356\" title=\"table 3\">",
"      Variants hereditary hemochromatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15943?source=related_link\">",
"      Bradykinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40179?source=related_link\">",
"      Patient information: Hemochromatosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/41/2709?source=related_link\">",
"      Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=related_link\">",
"      Regulation of iron balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12535?source=related_link\">",
"      Screening for hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=related_link\">",
"      Treatment of hereditary hemochromatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_13_2267="Mortality in acromegaly";
var content_f2_13_2267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F67986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F67986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Survival determinants and causes of death in acromegaly",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Survival determinants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Last known GH level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptom duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Causes of death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular - 38 to 62 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory - 0 to 25 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy - 9 to 25 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_13_2267=[""].join("\n");
var outline_f2_13_2267=null;
var title_f2_13_2268="American Burn Association grade";
var content_f2_13_2268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F74855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F74855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American Burn Association burn injury severity grading system",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Minor burn",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15 percent TBSA or less in adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10 percent TBSA or less in children and the elderly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 percent TBSA or less full-thickness burn in children or adults without cosmetic or functional risk to eyes, ear, face, hands, feet, or perineum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Moderate burn",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15-25 percent TBSA in adults with less than 10 percent full-thickness burn",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10-20 percent TBSA partial-thickness burn in children under 10 and adults over 40 years of age with less than 10 percent full-thickness burn",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10 percent TBSA or less full-thickness burn in children or adults without cosmetic or functional risk to eyes, ears, face, hands, feet, or perineum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Major burn",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25 percent TBSA or greater",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20 percent TBSA or greater in children under 10 and adults over 40 years of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10 percent TBSA or greater full-thickness burn",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All burns involving eyes, ears, face, hands, feet, or perineum that are likely to result in cosmetic or functional impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All high-voltage electrical burns",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All burn injury complicated by major trauma or inhalation injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All poor-risk patients with burn injury",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TBSA: total body surface area; burn: partial or full-thickness; young or old: &lt;10 or &gt;50 years old; adults: &gt;10 or &lt;50 years old.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Hartford CE, Kealey CP. Care of outpatient burns. In: Total Burn Care, 3rd ed, Herndon DN (Ed), Elsevier, Philadelphia 2007. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_13_2268=[""].join("\n");
var outline_f2_13_2268=null;
var title_f2_13_2269="Katz daily living scale";
var content_f2_13_2269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Katz index of independence in activities of daily living",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Activities",
"      </td>",
"      <td class=\"subtitle1\">",
"       Independence",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dependence",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3\">",
"       Points (1 or 0)",
"      </td>",
"      <td class=\"subtitle3\">",
"       <p>",
"        Points (1)",
"       </p>",
"       <p>",
"        <em>",
"         NO",
"        </em>",
"        supervision, direction, or personal assistance",
"       </p>",
"      </td>",
"      <td class=\"subtitle3\">",
"       <p>",
"        Points (0)",
"       </p>",
"       <p>",
"        <em>",
"         WITH",
"        </em>",
"        supervision, direction, personal assistance or total care",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bathing",
"      </td>",
"      <td rowspan=\"2\">",
"       <strong>",
"        (1 point)",
"       </strong>",
"       Bathes self completely or needs help in bathing only a single part of the body such as the back, genital area or disabled extremity.",
"      </td>",
"      <td rowspan=\"2\">",
"       <strong>",
"        (0 points)",
"       </strong>",
"       Needs help with bathing more than one part of the body, getting in or out of the tub or shower. Requires total bathing.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       POINTS:_____",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dressing",
"      </td>",
"      <td rowspan=\"2\">",
"       <strong>",
"        (1 point)",
"       </strong>",
"       Gets clothes from closets and drawers and puts on clothes and outer garments complete with fasteners. May have help tying shoes.",
"      </td>",
"      <td rowspan=\"2\">",
"       <strong>",
"        (0 points)",
"       </strong>",
"       Needs help with dressing self or needs to be completely dressed.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       POINTS:_____",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Toileting",
"      </td>",
"      <td rowspan=\"2\">",
"       <strong>",
"        (1 point)",
"       </strong>",
"       Goes to toilet, gets on and off, arranges clothes, cleans genital area without help.",
"      </td>",
"      <td rowspan=\"2\">",
"       <strong>",
"        (0 points)",
"       </strong>",
"       Needs help transferring to the toilet, cleaning self or uses bedpan or commode.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       POINTS:_____",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Transferring",
"      </td>",
"      <td rowspan=\"2\">",
"       <strong>",
"        (1 point)",
"       </strong>",
"       Moves in and out of bed or chair unassisted. Mechanical transferring aides are acceptable.",
"      </td>",
"      <td rowspan=\"2\">",
"       <strong>",
"        (0 points)",
"       </strong>",
"       Needs help in moving from bed to chair or requires a complete transfer.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       POINTS:_____",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Continence",
"      </td>",
"      <td rowspan=\"2\">",
"       <strong>",
"        (1 point)",
"       </strong>",
"       Exercises complete self control over urination and defecation.",
"      </td>",
"      <td rowspan=\"2\">",
"       <strong>",
"        (0 points)",
"       </strong>",
"       Is partially or totally incontinent of bowel or bladder.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       POINTS:_____",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Feeding",
"      </td>",
"      <td rowspan=\"2\">",
"       <strong>",
"        (1 point)",
"       </strong>",
"       Gets food from plate into mouth without help. Preparation of food may be done by another person.",
"      </td>",
"      <td rowspan=\"2\">",
"       <strong>",
"        (0 points)",
"       </strong>",
"       Needs partial or total help with feeding or requires parenteral feeding.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       POINTS:_____",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"4\">",
"       <strong>",
"        Total points:",
"       </strong>",
"       _____",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     6 points:",
"    </strong>",
"    high (patient independent).",
"    <br>",
"     <strong>",
"      0 points:",
"     </strong>",
"     low (patient very dependent).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Katz S, Down TD, Cash HR, Grotz RC. Progress in the development of the index of ADL. Gerontologist 1970, 10:20. Copyright &copy; 1970 Oxford University Press.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_13_2269=[""].join("\n");
var outline_f2_13_2269=null;
var title_f2_13_2270="Viral infection cardiomyopathy";
var content_f2_13_2270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Virus-immune hypothesis in dilated cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 321px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Following acute viral myocarditis, subjects who are not genetically predisposed to autoimmunity develop a self-limited disease and recover completely. In contrast, in individuals with a genetic predisposition to autoimmunity, a viral infection may initiate a chronic autoimmune myocarditis leading to dilated cardiomyopathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Caforio ALP, Baboonian C, McKenna WJ. Eur Heart J 1997; 18:1053.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_13_2270=[""].join("\n");
var outline_f2_13_2270=null;
var title_f2_13_2271="MPS I hand";
var content_f2_13_2271=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hand deformity in a patient with mucopolysaccharidosis type I (MPS I, Hurler-Scheie syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The hand of a 17-year-old male with Hurler-Scheie syndrome, showing severe contractures and deformation of the distal interphalangeal joints. Movement of the hand and fingers is limited. Thenar atrophy seen at the base of the thumb is due to severe carpal tunnel syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Emil Kakkis, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_13_2271=[""].join("\n");
var outline_f2_13_2271=null;
